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ABSTRACT
Leveraging electronic health records to develop cardiovascular risk profiles for primary
prevention with youth living with HIV in multidisciplinary adolescent HIV care settings
By
Sitaji Gurung
Advisor: Christian Grov
Background: HIV infection has shown to be associated with increased risk for, and earlier
occurrence of cardiovascular disease (CVD). Emerging evidence suggests that detectable viral
load (VL) and CD4 ≤ 200 contribute substantially to increased risk of CVD. Cigarette smoking is
prevalent in at least 40% of those with HIV, and significantly more common compared to the
general population. As many as 33% of adolescents are overweight, and this excess weight leads
to lipid abnormalities, and increases in metabolic syndrome. With the newer formulation of
antiretroviral therapy (ART) agents available as a component of single tablet regimens (STR), it
is important to examine their impact on lipid abnormalities in youth living with HIV (YLH). The
cardiovascular risk profile for YLH has yet to be developed. These findings support a
cardiovascular risk framework incorporating biomarkers, behavioral measures, and ART
medications as independent factors of a single multivariable CVD risk function among YLH in
the United States (U.S.).
Methods: De-identified electronic health records of YLH who received care in 2016 were
extracted from multidisciplinary adolescent HIV clinics across the United States. Two analytic
samples were developed based on Cardiac Risk Score1 (n =813) and Cardiac Risk Score2 (n =
398) to examine the association of HIV biomarkers (VL and CD4 cell count) with cardiovascular
risk among YLH aged 14-26 (AIM 1). The second analytic sample of 398 was used to examine
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the association of cigarette smoking and metabolic syndrome with VL (AIM 2) and examine the
association of STR and detectable VL with lipid abnormalities (AIM 3) among YLH aged 14-26.
We used descriptive statistics, chi-square, ANOVA and independent t tests to examine the
independent contributions of biomarkers, behavioral measures, and ART medications on
cardiovascular risk among YLH in the U.S. We ran a series of multivariable linear regression
models and tested the hypotheses that detectable VL and CD4 ≤ 200 will be positively associated
with increased cardiovascular risk among YLH (AIM 1). We then tested the hypotheses that
smoking and presence of metabolic syndrome will be positively associated with an increased
odds of having detectable VL by performing multivariable linear regression models (AIM 2).
Finally, we tested the hypotheses that detectable VL will be positively associated with increased
risk of having low HDL and high total cholesterol whereas treatment with STR will be positively
associated with decreased risk of having low HDL and high total cholesterol by performing
multivariable logistic regression models (AIM 3).
Results: Detectable VL was significantly associated with increased cardiovascular risk, cigarette
smoking, and lipid abnormalities (AIMS 1-3); after simultaneously adjusting for demographic
and clinical covariates. CD4 cell count ≤ 200 was not found to be significantly associated with
increased cardiovascular risk (AIM 1). Cigarette smoking was associated with increased odds of
VL non-suppression; however, the presence of components of metabolic syndrome were not
found to be significantly associated with VL non-suppression after adjusting for demographic
and clinical covariates (AIM 2). Treatment with single tablet regimen (STR) was associated with
decreased odds of having low HDL cholesterol and high total cholesterol (AIM 3).
Conclusions: Overall, this dissertation demonstrates that a relationship exists between detectable
VL and increased risk of CVD; and it appears that smoking is positively associated with VL non-
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suppression, which then is positively and independently associated with lipid abnormalities
whereas STR is associated with lipid abnormalities as a protective agent in YLH. The variety of
biomedical and behavioral factors that make HIV-positive individuals more susceptible to
developing CVD is compelling evidence to reconfigure how the two ailments are addressed. The
targeted population YLH carries a lot of interconnected factors that act as a tide in the ocean
against seeking them, and it requires a multidisciplinary treatment method to increase its
effectiveness in biological, societal, and even psychological way.
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CHAPTER 1 – INTRODUCTION
Overview
HIV infection has shown to be associated with increased risk for, and earlier occurrence
of cardiovascular disease (CVD).1-3 Moreover, analysis of CVD in HIV-positive individuals
indicates a two-fold risk for CVD events when compared to the general population.3-5 Emerging
evidence suggests that HIV-related factors such as detectable viral load (VL) and immune
dysfunction defined as CD4 cell count of less than 200,6 contribute substantially to increased risk
of CVD for those with HIV resulting in premature atherosclerosis and accelerated aging.7-9
Cigarette smoking is prevalent in at least 40% of people with HIV10-13 and significantly more
common compared to the general population.14-16 The use of alcohol and drugs such as cocaine
and other illicit drugs may further augment this association between HIV-related factors and
premature development of CVD.17-20 The 2017 national Youth Risk Behavior Surveillance data
showed that the prevalence of health risk behaviors associated with CVD is significantly higher
among sexual minority students aged 10 to 24 years in the United States (U.S.).21 Nationwide,
29.8% of students reported current alcohol use, 19.8% reported current marijuana use, and 14%
had prescription drug misuse.21 In addition, 39.5% of students were sexually active and 9.7% of
them had four or more sexual partners, 14.8% had obesity and 15.6% were overweight.21 Given
the current guidelines of initiating antiretroviral therapy (ART) immediately after diagnosis in
adolescents and young adults and that with each year an individual on ART ages, their risk for
CVD increases because of ART’s effect on blood cholesterol and triglycerides,22-29 CVD
prevention is critical in this population. However, the focus on CVD prevention and treatment in
the context of HIV has exclusively targeted older adults who have experienced cardiovascular
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events,4,30-34 while research on CVD prevention strategies for adolescents and young adults with
HIV continues to be limited.

Research Theme and Conceptual Basis
With the growing burden of HIV-related CVD and 21% of all new HIV diagnoses in the
U.S. were among youth in 2016,35 the cardiovascular risk profile for youth living with HIV
(YLH) has yet to be developed. There is clearly a need for accurate risk stratification and
aggressive primary and secondary prevention strategies in this important population.36 The
conceptual framework for this study is informed by the Framingham multivariable risk
algorithm37-40 and the increasing evidence that chronic immune activation and inflammation play
a role in the pathogenesis of CVD in the context of HIV infection.41 Acute HIV infection results
in low CD4+ cells throughout the gastrointestinal tract, which allows microbial translocation
through the gut into the circulation, and this translocation may drive immune activation and
inflammation – also known as leaky gut syndrome.41 Although metabolic changes leading to the
development of atherosclerosis can start early in life, and are frequently undiagnosed in their
early stages, the Framingham risk score and similar cardiac risk estimating equations are poorly
validated in younger people due to their low absolute risk, age being the primary factor of the
equation, and the frequent lack of traditional CVD risk factors.42,43
The age alone is a non-modifiable risk factor contributing to the development of CVD in
general population.44 Using the Cox proportional hazards regression model,45,46 the Framingham
Heart Study constructed a gender-specific risk algorithm driven by age to estimate the 10-year
risk of developing CVD. However, for HIV-positive populations, screening all patients
regardless of age would allow health care providers to assess cardiovascular risk among YLH.
With the development of Cardiac Risk Scores by removing age as a limiting factor in risk
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calculations but keeping other factors (systolic blood pressure, total cholesterol, high-density
lipoprotein (HDL) cholesterol, hypertension medication, cigarette smoking, and diabetes) from
the Framingham risk score, primary care physicians can assess early risk for CVD among YLH.
Given that obesity in childhood and young adulthood has repeatedly been shown to increase the
risk of CVD later in life,42,43 it is valuable to assess routinely measured traits of metabolic
syndrome using body mass index (BMI), blood glucose, systolic blood pressure, hypertension
medications, HDL cholesterol, and triglycerides. These findings support a cardiovascular risk
framework incorporating biomarkers, behavioral measures, and ART medications as predictors
of a single multivariable CVD risk function in a U.S. based population of YLH (Figure 1).

Public Health Significance
CVD is the leading cause of death for both men and women in the United States47-49 with
one out of every four deaths from a CVD event.48 CVD is a group of disorders that affects the
heart or blood vessels.17 As a diagnostic category, CVD includes four major areas – coronary
heart disease (CHD), cerebrovascular disease, peripheral artery disease (PAD), and aortic
disease.50 CHD affects the blood vessels supplying heart muscle, and it is manifested by fatal or
nonfatal myocardial infarction (heart attack), angina pectoris, and/or heart failure.17,50 It is the
most common type of cardiovascular disease,17 killing more than 370,000 people annually.48 It is
the cause of more than two-thirds of all heart disease-related deaths.51,52 Of the estimated
735,000 annual incidence of myocardial infarction, 525,000 are new attacks and 210,000 are
recurrent attacks.53 CHD alone in the United States accounts for $108.9 billion in expenses each
year.54
Cerebrovascular disease disrupts the blood vessels supplying the brain, and it is
manifested by fatal or nonfatal stroke and transient ischemic attack.17,50 Stroke is the fifth leading
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cause of death in the United States and is a major cause of adult disability.49,53 Of the 800,000
CVD deaths each year, almost 130,000 Americans die from stroke – 1 in every 19 deaths from
all causes.48 Of the estimated 795,000 annual incidence of stroke, about 610,000 are first events
and 185,000 are recurrent stroke events.53 Stroke costs the United States an estimated $34 billion
each year.53
With ART being easily accessible and effective in many clinical settings,55,56 HIVpositive individuals have longer life expectancy and are more likely to develop other chronic
conditions, including CVD.8,17,57 Advances in treatment and prevention have led to a dramatic
reduction in acquired immunodeficiency syndrome (AIDS)-related morbidity and mortality, and
HIV has become a chronic condition.7,9,57 CHD outcomes and hospitalization rates have
consistently been shown to be significantly higher among HIV-positive individuals in
comparison to HIV-negative people.57,58 Researchers working on the Veterans Aging Cohort
Study (VACS) investigated whether HIV is associated with an increased risk of acute
myocardial infarction after adjusting for all standard Framingham risk factors among a large
cohort of HIV-positive and demographically and behaviorally similar uninfected veterans in
care.1,34 The study found that through a median follow-up of 5.9 years, 82,459 veterans had 871
acute myocardial infarctions and myocardial infarction incidence was consistently higher in
veterans with HIV in three age brackets.1 The World Health Organization projected HIV/AIDS
and CHD as 2 of the top 3 leading causes of both mortality and disability-adjusted life-years
globally in the year 2030, which will pose a major challenge to public health and in the real
world of practice.59
Among the many comorbidity conditions, CVDs have become of particular concern in
the HIV-positive population. Why does HIV increase cardiovascular risks? HIV places a patient
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at a higher risk for cardiovascular disease. This could be because of chronic inflammation of
blood vessels that often accompanies HIV, long-term exposure to antiretroviral agents or a
combination of both. In addition to environmental and genetic predisposition, HIV-positive
patients present other factors that influence cardiovascular disease.7,9 HIV itself influences a state
of persistent inflammation and immune activation, endothelial damage, increased thrombotic
activity, higher oxidative stress, and metabolic abnormalities.7-9 There is growing evidence
indicating HIV-accelerated inflammatory and immunologic processes (known to promote
atherosclerosis) contributing to additional risk for CVD events in HIV-positive patients.7-9 Such
a mechanism was demonstrated in the Strategies for Management of Antiretroviral Therapy
(SMART) trial.60
In SMART, HIV-positive patients were assigned to one of the two arms – continuous use
of ART (viral suppression group), and treatment interruption (drug conservation group) with
deferral of therapy until a CD4 count reduced to less than 250 cells per microliter.7-9 Patients in
the drug conservation group compared with the viral suppression group experienced a higher
hazard for AIDS or death, and more CVD events.7-9 Outcomes of subsequent studies from
SMART showed that ART interruption was associated with significant increase in blood levels
of interleukin-6 (a non-specific inflammatory biomarker) and D-dimer (a fibrin degradation
product reflecting increased thrombotic activity that may be elevated in response to
inflammatory stimuli and bacterial translocation.7-9 There is further evidence that HIV-positive
patients with advanced immunosuppression (CD4 <200) and not fully virally suppressed (viral
load >500) have a higher prevalence of elevated interleukin-6 and D-dimer.61
On the other hand, the long-term exposure to antiretroviral agents (such as abacavir or
protease inhibitors) still raises concerns for its potential deleterious metabolic and proatherogenic
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effects.7-9 However, although some ARTs may be associated with antiviral-drug-induced
metabolic changes, ART is a key factor in preventing CVD in people living with HIV and
therefore has a positive net impact on inflammation, immune activation, and endothelial
dysfunction.7-9 HIV itself may also be associated with other indicators of an increased risk of
CHD, including higher calcium levels in the coronary arteries and may contribute to dysfunction
of the heart muscle (myocardium).17 Finally, HIV-positive patients are frequently co-infected
with hepatitis C virus (HCV), cytomegalovirus (CMV), or herpes viruses that may contribute to
CVD by active inflammatory and immunological mechanisms, although HIV viral replication is
suppressed.7-9
HIV-positive patients share the same predisposing factor for the development of
dyslipidemia, diabetes, or metabolic syndrome as the general population62 but there are many
behavioral factors that a person can change. An extensive body of literature has established a
high prevalence of traditional cardiovascular risk factors in people living with HIV compared to
the general population.26,34,57,62,63 As explained above, other factors coexist such as the virus
itself, ART, and/or HCV coinfection in HIV-positive patients, which could explain the higher
prevalence of abnormal carbohydrate and lipid metabolism observed in HIV population.7 HIVpositive patients are more likely to have an increase in lipids that can collect in their artery walls
throughout their cardiovascular system. Lipid profiles are usually characterized by
hypertriglyceridemia and low HDL.64 High triglycerides as well as high LDL (bad) cholesterol
can increase a person’s likelihood for artery problems, and many PLWH have lower levels of
HDL (good) cholesterol. There is a growing evidence demonstrating the importance of the
cardiovascular risk factors, highlighting a strong association between HIV and CVD, one that is
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even stronger than the link between ART and CVD.7 However, it is important to note that both
ART and HIV infection may also induce dyslipidemia and diabetes.7
Chronic inflammation may cause plaque, perhaps from ART or as a result of long-term
exposure to the virus. Inflamed arteries are more likely to signal the body to send in additional
infection-fighting white blood cells or t-cells, which may be in short supply due to the HIV. As a
result, inflamed arteries trap more plaque leading to rupture and blood clot. Dietary habits appear
to be worse in HIV-positive patients with many patients having a greater caloric intake.7 A casecontrol study noted a significantly higher trans-, saturated-, and total fat and cholesterol
consumption in HIV-positive patients compared to the healthy volunteers.7 Smoking in particular
presents a greater risk of harm for HIV-positive patients both from the cardiovascular standpoint
and increased risk of various cancers and emphysema. It is very common in HIV-positive
patients7 and poses a significant challenge to HIV-positive patients and their providers.65
According to a nationally representative cross-sectional study, adults with HIV were nearly twice
as likely to smoke, compared to roughly 20% of the U.S. adult population, and that people living
with HIV were less likely to quit smoking than the general population.66
High blood pressure presents a potentially greater risk of HIV-positive patients than for
someone who is HIV-negative. Interestingly, a recent meta-analysis showed lower prevalence of
hypertension in HIV-positive patients compared to HIV-negative individuals.67 Several factors
that are beyond one’s control can increase risk for heart attack and stroke. These include age,
sex, and ethnicity. Tobacco screening and cessation strategies are important considerations as
part of routine HIV care.66 Because the prevalence of smoking in HIV-positive patients is
extremely high, the reduction of smoking would lead to the highest absolute reduction in CVD.9
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However, this goal is not easily attainable without mutual respect in patient-provider
relationships.
The pathophysiology of accelerated CVD in young people with HIV is complex and
multifactorial.68 CVD risk is increased in HIV-positive individuals.69-71 The underlying cause
that drives the excess risk of CVD in the HIV-positive population is currently unclear, but likely
involves a combination of factors. Some of the factors associated are predicted to be intrinsic to
the individual and contribution of HIV itself and ART.71 Intrinsic factors include both nonmodifiable factors such as age, sex (males have increased risk of CVD), and modifiable factors
(e.g., cigarette smoking, drug use, poor diet, and obesity).71 Traditional CVD risk factors tend to
be more prevalent amongst HIV-positive individuals.34 Extensive research over the past decade
has been conducted on modifiable factors such as high levels of cholesterol in the blood, high
blood pressure, insulin resistance and high blood sugar, and abnormal accumulation of body fat
in HIV-positive individuals.71 HIV infection alone, despite traditional risk factors, contributes to
CVD risk.71 This risk increases as CD4 cells decrease,71 highlighting the importance of
monitoring CD4 cell count and routinely collecting these data in the electronic health records
(EHR) system in the U.S.
HIV-positive individuals also suffer from immunologic changes from ART
medications.71 ART is associated with increased CVD risk, although each drug differs in its
contribution with lipid profile alterations, insulin resistance, and body fat.71 The degrees to which
ART contribute to the increased risk of CVD in the HIV-positive population are unknown. Some
data suggest an increased risk of CVD events with the use of protease inhibitors.44 Other classes
of HIV medications such as first-line nucleoside reverse transcriptase inhibitors and integrase
inhibitors are, however, associated with a favorable lipid profile.44 For example, tenofovir and
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emtricitabine, do not have an adverse effect on lipid profiles.44 With the newer formulation of
ART agents included as a component of single tablet regimens (STR), it is important to examine
their impact on lipid abnormalities in YLH. It is recommended that HIV-positive individuals
with CVD risk over 20% should adjust their ART, adhere to CVD therapeutic objectives, and
make appropriate lifestyle changes.23,72,73 However, it is important to note that drug interactions
(ART and drugs associated with CVD risk reduction) may have a significant clinical impact.
Atherosclerosis, the pathological process that involves inappropriate lipid metabolism
and activation of the innate and adaptive immune systems in the arterial wall,70,74 accelerates
during adolescence. CVD risk in youth aged 18 to 24 years is underestimated despite the high
prevalence of CVD risk factors75-78 and early signs of atherosclerosis in this group.79,80
Adolescence and young adulthood are critical developmental phases and can have a significant
impact on cardiovascular health.81 Obesity has more than tripled in youth over the past 30
years.82 CVD risk increases by 2-4% for each year a youth is obese.83 As many as 33% of
adolescents are overweight,76 and this excess weight leads to dyslipidemia84 and increases in
metabolic syndrome,85 diabetes,86 and CVD78 risk. CVD contributes to half of CVD deaths and is
one of the leading causes of death in adolescents.87 More than half of youth have at least one
CVD risk factor, and this directly affects cardiovascular health throughout the lifespan.88
Adolescence is the key age because many CVD risk factors surface in adolescence87,89-91 and
track forward to adulthood.92 The American Health Association’s 2020 Strategic Impact Goals
along with the National Health, Lung, and Blood Institute’s 2012 Expert Panel on Integrated
Guidelines for Cardiovascular Health and Risk Reduction in Adolescents93 emphasize early
prevention in adolescence88 to prevent the development of CVD later in life and help curtail the
high costs.
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Specific Aims
Although there have been studies establishing links between HIV and CVD events, they
mostly focus on older populations. The research on CVD prevention strategies for younger adults
living with HIV is currently limited. This is of great concern since youth and young adults living
with HIV face many challenges related to health and overall wellness, and is critical to the
overall understanding of the impact of HIV infection on lifestyle and the relationship between
HIV infection and CVD. Routine, systematic, and comprehensive cardiac evaluation, including
a thorough history and directed laboratory assays, is essential for the care of HIV-positive
adolescents and young adults as cardiovascular illness has become a part of care for older adults
living with HIV.94 Recommendations for CVD prevention in the general population include
lifestyle modification such as smoking cessation and increased physical activity and an emphasis
on prevention in adolescents and early adulthood when physical activity declines, smoking
initiation occurs, and smoking addiction is initiated.95,96 Given the current guidelines of initiating
ART immediately after diagnosis in adolescents and young adults and the relationship between
ART and increased CVD risk, CVD prevention is critical in this population.
To address these salient gaps, this dissertation contains three specific aims:
AIM 1: Examine the association of HIV biomarkers (VL and CD4 cell count) with
cardiovascular risk among YLH aged 14-26.
Hypothesis 1a: Test the hypothesis that detectable VL will be positively associated with
increased risk of CVD as compared to those with undetectable VL.
Hypothesis 2b: Test the hypothesis that low CD4 cell count ≤ 200 will be positively
associated with increased risk of CVD as compared to those with CD4 cell count > 200.
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To achieve this aim, regression was used to develop cardiovascular risk profile in a clinic sample
of U.S. based YLH. Detectable VL and CD4 cell count ≤ 200 were categorized into dichotomous
variables and used as independent variables. Gender, systolic blood pressure, cigarette smoking,
diabetes, diabetes, anti-hypertensive medication use, total cholesterol, and HDL cholesterol were
used to construct Cardiac Risk Scores, the outcome variables, to build a multivariable linear
regression model.
AIM 2: Examine the association of cigarette smoking and metabolic syndrome with VL among
YLH aged 14-26.
Hypothesis 2a: Test the hypothesis that smoking will be positively associated with
increased odds of having detectable VL as compared to those who do not smoke
cigarette.
Hypothesis 2b: Test the hypothesis that presence of metabolic syndrome will be
positively associated with increased odds of having detectable VL as compared to those
who do not have metabolic syndrome.
To achieve this aim, metabolic syndrome variable with three categories were constructed based
on the National Health, Lung, and Blood Institute (NHLBI) definition. Smoking and metabolic
syndrome were used as independent variables. A dichotomous variable of detectable VL was
used as the outcome variable to build a multivariable logistic regression model.
AIM 3: Examine the association of STR and detectable VL with lipid abnormalities among YLH
aged 14-26.
Hypothesis 3a: Test the hypothesis that detectable VL will be positively associated with
increased risk of having low HDL cholesterol as compared to those with undetectable
VL.
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Hypothesis 3b: Test the hypothesis that detectable VL will be positively associated with
increased risk of having high total cholesterol as compared to those with undetectable
VL.
Hypothesis 3c: Test the hypothesis that treatment with STR will be positively associated
with decreased risk of having low HDL cholesterol as compared to those not on STR.
Hypothesis 3d: Test the hypothesis that treatment with STR will be positively associated
with decreased risk of having high total cholesterol as compared to those not on STR.
To achieve this aim, the HIV medication data were used to create a patient-level dataset.
Combination of three or more HIV medicines from at least two different HIV drug classes were
coded as single tablet regimen. Detectable VL and STR were used as independent exposure
variables to build a multivariable logistic regression model. A dichotomous variable of total
cholesterol and HDL cholesterol were used as the outcome variables.

Methods
Study Design and Population
To address the aforementioned specific aims, this dissertation consists of a secondary
data analysis of de-identified EHR data extraction of YLH aged 14-26 receiving HIV medical
care at 10 clinics participating in a network trial, the Scale It Up research project,97 which is
currently underway for a longitudinal study, the 154 ATN Cascade Monitoring.98 Specific
variables of interest from the 2016 baseline data files received from 10 clinical sites for the 154
ATN Cascade Monitoring study98 were merged into a single analytic dataset. The study
population included YLH if the extracted data contained standard of care and treatment visits at
one of the participating sites between January 1, 2016 and December 31, 2016. To be included in
these analyses, data on a patient’s age, race, ethnicity, gender, height, weight, CD4 cell count,
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VL, systolic blood pressure, blood pressure medications, cholesterol panel, ART medications,
and the International Statistical Classification of Disease and Related Health Problems Tenth
Revision (ICD-10) diagnosis codes for diabetes, cigarette smoking, alcohol and drugs were
required.
Data Analysis
The baseline sample size was 1093. In order to address our aim 1, we used two analytic
samples (n = 813 for Cardiac Risk Score 1 and n = 398 for Cardiac Risk Score 2). In order to
address our Aim 2 and aim 3, we used a sub-sample of 398 YLH. All analyses were performed in
IBM SPSS Statistics 25 and syntax files were developed to construct new variables and recode
some variables based on the analytic design for each study. The Framingham 10-year risk of
general cardiovascular disease (2008 paper) calculator99 was used to construct Cardiac Risk
Scores to satisfy Aim 1. The National Center for Chronic Disease Prevention (CDC) percentile
data files on growth charts100 were downloaded to calculate BMI by sex and age to satisfy our
aims.
We first described the sample overall based on demographic and clinical characteristics
for all 3 studies. For Aim 1, we stratified the sample by VL and CD4 Cell count data to examine
bivariate associations with cardiovascular risk using chi-square, ANOVA, and independent t
tests. Next, we ran a series of three multivariable linear regression models with Cardiac Risk
Score1 as a continuous outcome variable. Subsequentley, a separate series of three multivariable
linear regression models examined the associatieon of each independent variable by Cardiac
Risk Score2 as a continuous outcome variable. For Aim 2, we stratified the sample by VL status
to examine bivariate associations with smoking and metabolic syndrome using chi-square,
ANOVA, and independent t tests. Next, we ran a series of three multivariable linear regression
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models with VL as a continuous outcome variable. For Aim 3, we stratified the sample across
cholesterol outcomes documented in the EHR system to examine bivariate associations with
detectable VL and STR using chi-square, ANOVA, and independent t tests. Next, we ran a series
of three multivariable logistic regression models with total choesterol as a dichotomus outcome
variable. Subsequently, a separate series of three multivariable logistic regression models
examined the associatieon of detectable VL and treatment with STR by low HDL choesterol as a
dichotomus outcome variable.

Conclusion
Although randomized controlled trials are considered the gold standard of research
design, technological advances have opened the possibility for new trial designs, including
integrating data from EHRs. This dissertation is the first to use multivariable modeling to
examine the independent contributions of biomarkers, behavioral measures and ART
medications on CVD risk in a U.S. based population of adolescents and young adults with HIV
treated in routine practice. The use of multivariable models based on routinely available EHR
data integrated into a common data model is an innovative approach to improving our
understanding of important population health risk factors that may be modifiable in routine
practice. The information gained may also provide valuable insight on how to design future
clinical trials. The findings of this dissertation will help tailor current practice guidelines for
CVD prevention in adolescents and young adults living with HIV.
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Figure 1. Conceptual Model
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CHAPTER 2 - Cardiovascular risk profile: A clinic-based sample of
youth living with HIV in the United States
Abstract
Background: Accelerated atherosclerosis has been found in young individuals diagnosed with
HIV. Previous research indicates that lower CD4 and higher plasma viral load (VL) significantly
increased the risk of cardiovascular disease (CVD); however, this link is largely underinvestigated among youth living with HIV (YLH). We examined whether detectable VL and low
CD4 count have significant associations with increased CVD risk among YLH aged 14-26y.
Methods: This study used electronic health records from the Adolescent Medicine Trials
Network 154 Cascade Monitoring baseline data extracted from multidisciplinary adolescent HIV
care settings across the United States. Multivariable linear regression was used to assess the
association between detectable VL and CD4 of ≤ 200 with Cardiac Risk Score1 (for those who
had data on systolic blood pressure, cigarette smoking, diabetes, and anti-hypertensive
medication use, n =813) and Cardiac Risk Score2 (for those who had data on systolic blood
pressure, cigarette smoking, diabetes, anti-hypertensive medications use, total cholesterol, and
HDL cholesterol, n = 398) adapted from the Framingham gender-specific algorithm.
Results: The sample was predominantly Black and male with mean age of 21y. Overall, 47.8%
had a detectable VL and 8.6% had a baseline CD4 of ≤ 200 indicating immune dysfunction. In
bivariate analyses, we found significant associations between VL and CVD risk as measured by
both cardiac risk scores (Cardiac Risk Score1, p < 0.001; Cardiac Risk Score2, p < 0.01).
Comparing patients who had CD4 ≤ 200 with those who had CD4 > 200, the risk of CVD was
significantly increased in patients who had CD4 ≤ 200 compared with those who had CD4 > 200
as measured by Cardiac Risk Score2 (p < 0.01) but not with Cardiac Risk Score1. In the
multivariable linear regression models, after adjusting for demographic and clinical covariates,
25

we found that for a 1000-point increase in VL copies/mL, there is a 38% increase in the
likelihood of having CVD risk (Cardiac Risk Score2, B = 0.038, 95% CI = 0.011, 0.066; p <
0.01. A small effect was observed for VL on increased CVD risk when measuring the strength of
this association (β = 0.134). We observed similar findings with Cardiac Risk Score1. CD4 of ≤
200 was not found to be significantly associated with CVD risk.
Conclusions: Higher plasma viral loads were associated with a small but statistically significant
increased risk of CVD, independent of exposure to ART and presence of demographic and
clinical covariates. Our findings demonstrate the independent contribution of detectable VL on
cardiovascular risk and highlight the importance of maintaining VL suppression, monitoring
metabolic health, and promoting self-management in YLH.

Keyword(s): Cardiovascular disease, viral load, cardiac risk score, CD4, youth living with HIV
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Introduction
Cardiovascular disease (CVD) among HIV-positive populations is an issue that needs
attention in the United States (U.S.). Although HIV-associated morbidity and mortality have
decreased considerably with the introduction and widespread use of effective antiretroviral
therapy (ART), 1-4 mortality rates among those with HIV remain 3 to 15 times higher than that of
the general population.5-7 More than 50% of these deaths are due to comorbid conditions that are
associated with inflammation,8-11 with CVD being the most prominent amongst these
comorbidities.12-14 CVD has emerged as an important cause of death among HIV-positive
populations (6.5% of a sample of 1876 deaths).12 The World Health Organization projected HIV
and CVD as two of the top three leading causes of both mortality and disability-adjusted lifeyears globally by 2030, which will pose a major challenge to public health.15 One study using
national mortality data in the U.S. found that the proportion of deaths related to CVD increased
more than twofold in HIV-positive populations compared to the general populations between
1999 and 2013.16 The evidence to date suggests that CVD has become an increasingly common
cause of death in HIV-positive populations since 1999.16,17 Therefore, understanding evolving
cardiovascular risks in the HIV-positive populations is essential to improve routine clinical care
of HIV-positive individuals as well as CVD prevention and treatment.16,17
Youth living with HIV (YLH) show early signs of CVD and are an important subset of
the HIV-positive populations. The prevalence of undiagnosed HIV infection is significantly
higher among individuals aged 13-24 years compared to the overall 20% undiagnosed HIV
infection prevalence in the U.S.18,19 Despite the fact that dramatic decreases in HIV transmission
are achievable with early initiation of ART,20-22 recent research shows significant gaps in the
HIV treatment cascade in younger individuals compared to older HIV-positive populations.18,19,22
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In fact, young individuals aged 18-24 compared to older individuals have a lower uptake of HIV
testing, diagnosis and treatment initiation which continues to present a significant challenge to
epidemic control.19,22 Only 40% of HIV-positive individuals aged 13 to 29 in the U.S. are aware
of their diagnosis22 compared to 80% of the national estimate of those 13 years and older who
are aware they are HIV-positive.22,23
A large cohort study examined California state-sponsored health insurance claims data of
28,513 HIV-positive and 3,054,696 HIV-negative patients.24 Although the incidence of CVD
events such as myocardial infarction (MI) in patients aged 18-24 years was low overall, it was
increased in those with HIV compared with those who were HIV-negative (relative risk, 6.76;
95% confidence interval [CI], 3.36-13.58 for men and relative risk, 2.47; 95% CI, 1.23-4.95 for
women).24 In addition, accelerated atherosclerosis has been found in young individuals
diagnosed with HIV without traditional CVD risk factors.25 Therefore, it is important to monitor
cardiac activity, HIV and immunologic biomarkers (i.e., CD4 cell count and viral load [VL]) of
young individuals diagnosed with HIV and continue to collect data from this population.
The pathophysiology of accelerated CVD in young individuals with HIV is currently
unknown. However, there is a growing body of evidence to suggest increased CVD risk among
those with lower CD4 cell counts and higher viral loads.13,26-29 In a nested case-control study of
289 HIV-positive French patients with a prospectively recorded first-time MI matched with 884
HIV-positive controls with no history of MI, lower nadir CD4 count and higher plasma VL were
associated with a significant increase in MI after adjusting for ART and traditional risk factors.28
Similarly, in a retrospective analysis of 3,068 HIV-positive patients in the Netherlands, those
with immune dysfunction characterized by CD4 cell count of less than 200 cells/mm3 after two
years of ART initiation had higher estimated five-year cardiovascular event rates (4.7%) than
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those with improved CD4 cell count (2 to 2.6%).29 Furthermore, a large observational cohort
study of 2,006 HIV-positive patients who received care at the Vanderbilt Comprehensive Care
Clinic in Tennessee between 1998 and 2012 suggested an association between low CD4 to CD8
ratio and cardiovascular risk, particularly among younger patients.30
The evidence suggests that YLH may have higher cardiovascular risk, which is currently
under-recognized and under-researched in the U.S. There are currently no published data
regarding the classic cardiovascular risk factors of dyslipidemia, hypertension, diabetes, and
smoking among YLH aged 14-26 years. Although metabolic changes leading to the development
of atherosclerosis can start early in life, and are frequently undiagnosed in their early stages, the
Framingham risk score and similar cardiac risk estimating equations are poorly validated in
younger people due to their low absolute risk and the frequent lack of traditional CVD risk
factors.31,32 The current study was undertaken to develop cardiovascular risk profiles in a sample
of US-based YLH and to compare their cardiovascular risk profiles by VL And CD4 status. We
hypothesized that detectable VL and CD4 count ≤ 200 would be associated with increased CVD
risk.

Methods
Study Design and Population
The Adolescent Medicine Trials Network (ATN) Scale It Up research program consists of
six study protocols as previously described33 and one of them is the ATN 154 Cascade
Monitoring electronic health records (EHR) initiative.34 De-identified EHR data were requested
from 10 participating sites for the baseline year 2016 (see Table 1). The 10 sites routinely
provide the HIV care continuum (also known as the HIV treatment cascade) to YLH that begins
with a diagnosis followed by linkage to an HIV healthcare provider who can engage youth in
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regular HIV medical care, initiating ART, and achieving viral suppression. The Institutional
Review Boards of both Florida State University and the City University of New York approved
to conduct analyses of de-identified data.
The study population included YLH if the extracted data contained standard of care and
treatment visits at one of the participating sites between January 1, 2016 and December 31, 2016.
Baseline data extraction cycle was launched in December 2017 and was completed in April
2018. Once the extracted data files were received and verified for each site, data from 10 sites
were cleaned and merged to produce a single analytic dataset of 1,093 YLH. To be included in
these analyses, data on a patient’s age, race, ethnicity, gender, height, weight, CD4 cell count,
VL, systolic blood pressure, blood pressure medications, cholesterol panel, ART medications,
and the International Statistical Classification of Disease and Related Health Problems Tenth
Revision (ICD-10) diagnosis codes for diabetes, cigarette smoking, alcohol and drugs were
required. Because Brooklyn, Miami, and Philadelphia did not provide gender and systolic blood
pressure data, these 3 sites were excluded from further analyses.
Measures
Demographics. We defined age as a continuous variable in years as reported by site.
Gender, race, and ethnicity definitions varied within a site’s data download. These demographic
variables were constructed as reported by site. For gender we constructed a binary variable of
male and female. Race/ethnicity variable was categorized into Black, Latino, White, Hispanic,
and patients of any other race were reported as Other. Missing race for two patients were kept as
missing data and removed from these analyses.
HIV and immunologic biomarkers. Earliest VL values in “copies/mL” by date were used
from each site. VL was missing for 5.8% of the sample. Missing VL results for 47 patients were
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not included in these analyses. VL was log-transformed for analysis as a continuous outcome.
Detectable VL threshold as reported by site was coded as a dichotomous variable. Based on the
guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, we
defined immunocompromised as CD4 T lymphocyte cell count of less than or equal to 200.35,36
CD4 cell count, a measure of immune status was missing for 27% of the sample. Missing CD4
results for 220 patients were not included in these analyses. CD4 cell count was divided by 100
to enhance the interpretability of the coefficients to correspond to a 100-cell increase rather than
a 1-cell increase.
ART medication. All prescribed HIV medications were coded into a dichotomous variable
where 0 = no prescribed medication and 1 = at least one prescribed medication. Missing values
for 92 patients were assumed to not have received prescriptions and was combined with the nonART category.
Substance abuse diagnosis: We used ICD-10 codes F1010, F1210, F1220, F1290, F1510,
F1511, F1520, F1590, F17200, F17210, F1910, and F1920 to identify alcohol and drug
dependence such as amphetamines, cannabis, cocaine, hallucinogens, and opioid. Substance
abuse was treated as a dichotomous variable. Missing values (n=714 values) were assumed as
non-substance-abuse because there are issues around documentation and disclosure of alcohol
and drugs use in clinical settings. The use of diagnostic codes as a proxy for substance abuse
diagnoses underestimates the prevalence of alcohol and drug use problems.36
Body mass index (BMI). BMI was calculated based on weight and height (kg/m2). If
multiple values for a given patient were present in EHR, values from the earliest date were used.
Seven patients with missing values were removed from further analyses.
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Cardiac risk scores. We adapted the gender-specific cardiovascular risk algorithm
developed by the Framingham Heart Study,86,8 to construct a cardiovascular risk variable
referred to as Cardiac Risk Score1 using clinic-based predictors that are routinely obtained in
primary care and do not require laboratory testing. These variables included systolic blood
pressure, anti-hypertensive medication use, current smoking, and diabetes status. Missing data
were present for gender and systolic blood pressure.
We also constructed a second cardiovascular risk variable referred to as Cardiac Risk
Score2 that used routinely obtained clinic-based predictors incluidng laboratory testing. These
variables included systolic blood pressure, anti-hypertensive medication use, current smoking,
diabetes, total cholesterol, and HDL cholesterol. Missing data were present for gender, total
cholesterol, HDL cholesterol, and systolic blood pressure (see Figure. 1, CONSORT-style
diagram illustrating a comprehensive assessment of all missingness in the construction of
Cardiac Risk Score1 and Cardiac Risk Score2). Because age is the strongest predictor of CVD
risk and that almost all multivariable risk algorithms are used to assess risk of CVD events in
older adults, it was removed from the equations. We set age = 21y. Following the convention of
the existing CVD prediction algorithm developed based on data obtained from the Framingham
Heart Study, we constructed a separate gender-specific multivariable risk funciton aglorithm for
males vs. females.37 The syntax for both Cardiac Risk Score1 and Cardiac Risk Score2 can be
found in the Appendix.
Data Analysis
HIV-positive patients who had health records of systolic blood pressure, antihypertensive medication use, current smoking, and diabetes status in 2016, were included in the
first analytic sample for Cardiac Risk Score1 (n =813). We then constructed a second analytic
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sample for Cardiac Risk Score2 (n = 398) in order to incorporate total cholesterol and HDL
cholesterol with the above-mentioned routinely obtained clinic-based predictors.
First, we performed a descriptive analysis of demographic and clinical characteristics of
the sample. Second, we conducted bivariate analyses of the sample using chi-square and
independent samples t-tests with detectable VL and low CD4 count as a nominal variable.
Finally, we ran a series of three multivariable linear regression models with Cardiac Risk Score1
as a continuous outcome variable. The first model was constructed to determine whether
detectable VL was associated with cardiovascular risk. The second model was constructed to
examine whether immune dysfunction characterized by CD4 cell count ≤ 200 was associated
with cardiovascular risk. The third model examined the combined effect of detectable VL and
low CD4 count with cardiovascular risk. The three regression models were repeated with
Cardiac Risk Score2 as the outcome. Covariates included age, race/ethnicity, gender, being
prescribed ART medication, substance dependence, and BMI.
The linear regression coefficients were evaluated using unstandardized beta (B) as the
point estimate and an interpretation of its meaning and/or magnitude; confidence interval (CI) for
the variability around that point estimate so we know how precise it is; and p-value for statistical
significance. Using Cohen’s criteria as described as small (.10), medium (.30), and large (.50),
standardized beta (β) served as an effect size estimate of independent variables on the dependent
variable. All analyses were performed in IBM SPSS Statistics 25 and syntax files were
developed to construct new variables and recode some variables based on the analytic design.
Alpha was set at p<0.05.
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Results
Demographic and clinical characteristics of the analytic sample (n = 813) are displayed in
Table 1. The mean age was 21 with a range of 14 to 26 years (SD = 2.6). The sample was
predominantly of racial and ethnic minorities – 70.3% identified as Black, 10.9% identified as
Latino, 10% identified as White, and 8.9% identified as any other race. More than two thirds
(69.2%) of the sample were men and 30.8% were reported by site as women. Among those with
VL data, nearly half (47.8%) had a detectable VL, while 52.2% had an undetectable VL. Among
those with a detectable VL, 247 (30%) had > 1,000 copies/mL. Among those with a CD4 cell
count value available, 91.4% had a baseline count of > 200, while 8.6% had a baseline count of ≤
200 indicating immunocompromised status. Of the 813 YLH, 88.6% were currently taking ART
and 11.4% were not on ART medication. Among those sites with the required data for this study,
Tampa (n = 219) and Memphis (n = 187) had the largest sample size (26.9% and 23%,
respectively). The mean BMI was 25 kg/m2 (SD = 6.7). The mean Cardiac Risk Score1 based on
systolic blood pressure, anti-hypertensive medication use, current smoking, and diabetes status
was 0.062 (SD = 0.039). The mean Cardiac Risk Score2 based on systolic blood pressure, antihypertensive medication use, current smoking, diabetes, total cholesterol, and HDL cholesterol
was 0.672 (SD = 0.401).
Bivariate correlates of HIV and immunologic biomarkers
Demographic and clinical correlates. Examining the demographic and clinical indicators
by HIV biomarker, several general trends emerged as shown in Table 2. First, patients who had
detectable VL, compared to those who had undetectable VL, were more likely to be Black
(74.5% vs. 67.0%; χ² = 9.881; p < 0.05). Second, almost three-quarters of patients with
detectable VL were men (72.7%) compared to 65.2% of patients without detectable VL (χ² =
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4.912; p < 0.05). In addition, 87.7% of those with detectable VL were on ART medication
compared to 92.5% of those with undetectable VL (χ² = 4.975; p < 0.05). Last but not least,
15.8% of those with detectable VL had CD4 cell count ≤ 200 compared to only 2.5% among
those with undetectable VL (χ²[1] = 32.326; p ≤ 0.001).
The 10-year risk of developing CVD was estimated using two cardiovascular risk
variables, Cardiac Risk Score1 (n = 813) and Cardiac Risk Score2 (n = 398). In bivariate
analyses, we found significant associations between VL and CVD risk as measured by both
cardiac risk scores (Cardiac Risk Score1, p < 0.001; Cardiac Risk Score2, p < 0.01). No
significant differences (p > 0.05) were found between the demographic characteristics and the
immunologic biomarker, CD4 cell count, as displayed in Table 3. Comparing patients who had
CD4 cell count ≤ 200 with those who had CD4 cell count > 200, no significant difference was
found in Cardiac Risk Score1. With Cardiac Risk Score2, the risk of CVD was significantly
increased in patients who had CD4 cell count ≤ 200 compared with those who had CD4 cell
count > 200 (p < 0.01).
Multivariable analyses of cardiac risk scores
Cardiac Risk Score1. Multivariable regression analysis of Cardiac Risk Score1 from
demographic and clinical characteristics including HIV and immunologic biomarkers is shown in
a series of model 1 in Table 4. Model 1A: Cardiac Risk Score1 with VL results plus demographic
and clinical covariates. After adjusting for age, race/ethnicity, gender, ART medication,
substance abuse diagnosis, and BMI, we found significant positive association between VL and
CVD risk as measured by Cardiac Risk Score1 (p < 0.01). We found that for a 1-unit increase in
VL, there is a 0.002 increase in log-likelihood of having CVD risk (B = 0.002; 95% CI = 0.000,
0.003). On a scale that may be more meaningful for clinicians and patients themselves, this
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indicates that a 1,000-point increase in VL (for example, from having a VL of 1,000 to having a
VL of 2,000), there is a 2% increase in the likelihood of having CVD risk. While 0.002 is the
best estimate of this association, we are 95% confident that the true beta falls between 0.000 and
0.003. Because this 95% CI does not include 1, the association is statistically significant at the
0.05 level. Therefore, the model is useful for predicting that there is association between VL and
CVD risk. A small effect was observed for VL on increased CVD risk when measuring the
strength of this association since the standardized beta value was closer to 0.1 (β = 0.067). Model
1B: Cardiac Risk Score1 with CD4 results plus demographic and clinical covariates. After
adjusting for age, race/ethnicity, gender, ART medication, substance abuse diagnosis, and BMI,
CD4 cell count was not significantly associated with CVD risk. Model 1C: Cardiac Risk Score1
with VL and CD4 results together plus demographic and clinical covariates. After adjusting for
age, race/ethnicity, gender, ART medication, substance abuse diagnosis, and BMI, we found
significant positive association between VL and CVD risk as measured by Cardiac Risk Score1
(p < 0.01), while CD4 cell count was not (p = 0.653). We found that the findings of this model
were similar to model 1A. Although a small effect was observed when measuring the strength of
the association between VL and increased CVD risk, the effect size slightly increased with this
model (β = 0.088).
Cardiac Risk Score2. Multivariable regression analysis of Cardiac Risk Score2 from
demographic and clinical characteristics including HIV and immunologic biomarkers is shown in
a series of model 2 in Table 4. Model 2A: Cardiac Risk Score2 with VL results plus demographic
and clinical covariates. After adjusting for age, race/ethnicity, gender, ART medication,
substance abuse diagnosis, and BMI, we found significant positive association between VL and
CVD risk as measured by Cardiac Risk Score2 (p < 0.01). We found that for a 1-unit increase in

36

VL, there is a 0.038 increase in log-likelihood of having CVD risk (B = 0.038; 95% CI = 0.011,
0.066). On a scale that may be more meaningful for clinicians and patients themselves, this
indicates that a 1,000-point increase in VL (for example, from having a VL of 1,000 to having a
VL of 2,000), there is a 38% increase in the likelihood of having CVD risk. While 0.038 is the
best estimate of this association, we are 95% confident that the true beta falls between 0.011 and
0.066. Because this 95% CI does not include 1, the association is statistically significant at the
0.05 level. Therefore, the model is useful for predicting that there is association between VL and
CVD risk. A small effect was observed for VL on increased CVD risk when measuring the
strength of this association since the standardized beta value was 0.1 (β = 0.134). Model 2B:
Cardiac Risk Score2 with CD4 results plus demographic and clinical covariates. After adjusting
for age, race/ethnicity, gender, ART medication, substance abuse diagnosis, and BMI, CD4 cell
count was not significantly associated with CVD risk. Model 2C: Cardiac Risk Score2 with VL
and CD4 results together plus demographic and clinical covariates. After adjusting for age,
race/ethnicity, gender, ART medication, substance abuse diagnosis, and BMI, we found
significant positive association between VL and CVD risk as measured by Cardiac Risk Score2
(p < 0.05), while CD4 cell count was not (p = 0.544). We found that the findings of this model
were similar to model 2A. Although a small effect was observed when measuring the strength of
the association between VL and increased CVD risk, the effect size slightly increased with this
model (β = 0.146).

Discussion
This study focused on the development of CVD risk profiles and the associations of HIV
and immunologic biomarkers with cardiac risk scores in YLH aged 14-26y. Both cardiac risk
scores demonstrated similar findings upon examining the associations with HIV and
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immunologic biomarkers. Notably, VL was found to be significantly related to CVD risk after
adjusting for demographic and clinical covariates, highlighting the importance of linking
metabolic and HIV care in routine clinical practice.
The American Heart Association (AHA) developed a Health Campaign for Life’s Simple
7, which emphasizes early prevention in adolescence38-40 to prevent the development of CVD
later in life and help curtail the high costs associated with CVD. The AHA’s Life’s Simple 7
metrics include core health behaviors (smoking, physical activity, diet, and weight) and clinical
risk factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular
health.38 With the growing burden of HIV-related CVD and 21% of all new HIV infection being
diagnosed among youth in the U.S.,41 it is important to examine the overall cardiovascular risk
profile of YLH as opposed to focusing on any one single risk factor. The two US-based cohorts
of HIV-positive patients – the Women’s Interagency HIV Study (WIHS) and the Multicenter
AIDS Cohort Study (MACS) used the Framingham Risk Score equations to estimate the 10-year
risk of developing CVD among 1455 women and 931 men.42 The findings from these two
cohorts demonstrated that among HIV-positive men, 17% had high predicted CVD risk in
contrast with HIV-negative men (11%) whereas among HIV-positive women, 12% had high
predicted CVD risk which was similar to HIV-negative women.42 However, while the
Framingham Risk Score developed for use in the general population appears to be wellcalibrated in some populations, it overestimates or underestimates 10-year cardiovascular risk in
those with HIV, depending on individual risk factors with chronic immune activation and
inflammation.43,44
Our findings showed that detectable VL was associated with significantly increased risk
of CVD, both at the bivariate level and in multivariable linear regression models. Higher plasma
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VLs were associated with a small but statistically significant increased risk of CVD, independent
of exposure to ART and presence of demographic and clinical covariates. These findings
contribute to our understanding of the broad spectrum of the VL-CVD risk relationship. VL can
fluctuate over time depending on patients’ access to treatment, retention in care, response to HIV
treatment, and medication adherence. Prior research has shown that the Framingham Risk Score
is poor at stratifying lifetime risk in younger individuals and has been unable to estimate CVD
risk in populations below age 30.45 Immunologic biomarker, CD4 cell count, was only associated
with Cardiac Risk Score2 at the bivariate level. Upon combining routinely obtained clinic-based
predictors with laboratory testing, lower CD4 cell count was associated with a statistically
significant increased risk of CVD in patients who had a baseline count data.
The utility of our risk scores without age adds new knowledge in the assessment of CVD
risk prediction in young HIV-positive populations. Removing age from the risk equations as a
significant factor may have important implications for clinical decision-making regarding
treatment thresholds in YLH. Since the Framingham Risk Score and similar cardiac risk
estimating equations place significant weight on age in predicting absolute risk, the use of our
risk scores provide important insights to classify YLH at high risk for CVD. The current study
sets the stage for future research that could further test this approach and can be extended to nonHIV youth populations. Since we found similar results between the two risk scores the simpler
version can be utilized as a cost-effectiveness method for HIV-positive youth at high risk for
CVD by utilizing routinely obtained clinic-based predictors as laboratory testing is not required.
Nevertheless, researchers need to evaluate periodically for potential biases that were not apparent
in this study. In addition, the use of continuous risk scores may prevent from creating an
arbitrary classification of high CVD risk as predicted by the Framingham Risk Score.
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Although the current findings are based on a multi-clinic sample, there are potential
limitations. First, the study design was cross-sectional and thus no causal inference may be
drawn. Our findings may also not be generalizable to the entire YLH population in the U.S. or
elsewhere. Future research should attempt to test these associations in longitudinal data to
observe changes over time. Second, we were unable to define undetectable VL as a VL test result
of < 200 copies/mL due to incomplete medical records extracted from multiple sites with some
sites reporting in text (detectable/undetectable) as opposed to providing the actual VL values.
Some misclassification may have occurred. Third, we were unable to provide the lower limit
detection threshold because sites utilized various laboratories and assays with varying detection
limits to perform VL testing. Another limitation in the current data was the number of missing
data, particularly relating to cholesterol. We had to drop youth from three of the highest
prevalence areas in the U.S. EMRs with more complete data should be prioritized.
Finally, this analysis was also limited by the fact that we used unvalidated cardiac risk
scores and the data we had were not sufficient to conduct any validation of the score. Our
Cardiac Risk Score1 was developed based on routinely available clinical data. Our Cardiac Risk
Score2 included both routinely available and laboratory data. Age wasn’t a limiting factor in
calculating both of these risk scores. The calculations were not based on the age value – all
participants with enough data to calculate risk were assumed to be 21. Since no study has
validated the risk scores we used, there is a need for validation study to ensure these scores are
valid and clinically meaningful. By using a population-wide longitudinal dataset, future step
should include conducting external validation of our modified risk scores for both adolescent and
adult with no CVD events to determine model applicability at a different time. As described in
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prior studies, we can assess the overall ability of our cardiac risk prediction scores using Harrel’s
C-statistics.46-48
Despite these limitations, the current study is innovative in that it utilized the EHRs of
813 YLH from 7 ATN clinics to examine the independent contributions of HIV and immunologic
biomarkers on CVD risk in a U.S.-based cohort of YLH treated in routine practice. EHRs
provided us with the opportunity to include two innovative design features in this study: (a) the
inclusion of HIV outcomes data from clinic-based patients lowered the costs of conducting the
study; and (b) the ability to include ICD-10 codes to identify clinical covariates used in the
analyses. These findings have implications for the development of a single multivariable risk
prediction tailored to YLH. Future research is warranted to test a risk equation including VL in
relation to CVD outcomes. This study highlights the need for further research evaluating the
inclusion of HIV-specific variables, including HIV medications (e.g., number of years taking
ART) into tailored risk prediction algorithms. It has the potential for becoming an essential tool
which can be made available online such as through UpToDate, a software system used as a
point-of care medical resource. As the presence of a detectable VL was found to be significantly
associated with CVD risk, the findings of our study highlight the relevance of considering HIV
infection as an additional CVD risk factor and providing CVD prevention in YLH in routine
practice.
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Cardiac Risk Score1 Syntax
DO IF Male = 1 AND BP_Meds = 0.
COMPUTE RiskFactors_R1 = ((LN(21))*AgeFactorM) +
((LN(SysBP))*SysBPFactorM)+(Cig*CigFactorM)+(DM*DMFactorM)-AvgRiskM.
END IF.
EXECUTE.
DO IF Male = 0 AND BP_Meds = 0.
COMPUTE RiskFactors_R1 =
((LN(21))*AgeFactorW)+(SysBPFactorW*(LN(SysBP)))+(Cig*CigFactorW)+(DM*DMFactor
W)-AvgRiskW.
END IF.
EXECUTE.
DO IF Male = 1 AND BP_Meds = 1.
COMPUTE RiskFactors_R1 = ((LN(21))*AgeFactorM)+
((LN(SysBP))*SysBPFactorM_med)+(Cig*CigFactorM)+(DM*DMFactorM)-AvgRiskM.
END IF.
EXECUTE.
DO IF Male = 0 AND BP_Meds = 1.
COMPUTE RiskFactors_R1 =
((LN(21))*AgeFactorW)+(SysBPFactorW_med*(LN(SysBP)))+(Cig*CigFactorW)+(DM*DMF
actorW)-AvgRiskW.
END IF.
EXECUTE.
DO IF Male = 1.
COMPUTE Risk1 = 100*(1 - RiskPeriodFactorM**EXP(RiskFactors_R1)).
END IF.
DO IF Male = 0.
COMPUTE Risk1 = 100*(1 - RiskPeriodFactorW**EXP(RiskFactors_R1)).
END IF.
EXECUTE.
Cardiac Risk Score2 Syntax
DO IF Male = 1 AND BP_Meds = 0.
COMPUTE RiskFactors_R2 = ((LN(21))*AgeFactorM)+(TotalCholFactorM*(LN(TotalChol)))
+(HDLCholFactorM*(LN(HDLChol))) +
((LN(SysBP))*SysBPFactorM)+(Cig*CigFactorM)+(DM*DMFactorM)-AvgRiskM.
END IF.
EXECUTE.
DO IF Male = 0 AND BP_Meds = 0.
COMPUTE RiskFactors_R2 = ((LN(21))*AgeFactorW)+(TotalCholFactorW*(LN(TotalChol))
)+(HDLCholFactorW*(LN(HDLChol)) ) +
((LN(SysBP))*SysBPFactorW)+(Cig*CigFactorW)+(DM*DMFactorW)-AvgRiskW.
END IF.
EXECUTE.
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DO IF Male = 1 AND BP_Meds = 1.
COMPUTE RiskFactors_R2 = ((LN(21))*AgeFactorM)+ (TotalCholFactorM*(LN(TotalChol)))
+ ( (LN(HDLChol))*HDLCholFactorM ) +
((LN(SysBP))*SysBPFactorM_med)+(Cig*CigFactorM)+(DM*DMFactorM)-AvgRiskM.
END IF.
EXECUTE.
DO IF Male = 0 AND BP_Meds = 1.
COMPUTE RiskFactors_R2 = ((LN(21))*AgeFactorW)+(TotalCholFactorW*(LN(TotalChol)))
+ ( (LN(HDLChol))*HDLCholFactorW ) +
((LN(SysBP))*SysBPFactorW_med)+(Cig*CigFactorW)+(DM*DMFactorW)-AvgRiskW.
END IF.
EXECUTE.
DO IF Male = 1.
COMPUTE Risk2 = 100*(1 - RiskPeriodFactorM**EXP(RiskFactors_R2)).
END IF.
DO IF Male = 0.
COMPUTE Risk2 = 100*(1 - RiskPeriodFactorW**EXP(RiskFactors_R2)).
END IF.
EXECUTE.

Table 1. Clinic Sites
City
Baltimore
Birmingham
Brooklyn
Los Angeles
Memphis
Miami
Philadelphia
San Diego
Tampa
Washington DC

Organization
Johns Hopkins University, Maryland
University of Alabama at Birmingham, Alabama
SUNY Downstate Medical Center, New York
Children’s Hospital Los Angeles, California
St. Jude Children’s Research Hospital, Tennessee
University of Miami, Florida
Children’s Hospital of Philadelphia, Pennsylvania
University of California San Diego, California
University of South Florida, Florida
Children’s National Health System, District of
Columbia
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Figure 1. CONSORT-style diagram illustrating a comprehensive assessment of all
missingness in the construction of Cardiac Risk Score1 and Cardiac Risk Score2.
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Table 2. Demographic and Clinical Characteristics of the Sample (N = 813)
n

%

Black

570

70.3

Latino

88

10.9

White

81

10.0

Other

72

8.9

Male

563

69.2

Female

250

30.8

Currently on ART medication

720

88.6

Not reportedly on ART medication

93

11.4

Detectable VL

366

47.8

Race/Ethnicity (n = 811)

Gender

ART Medication

Viral Load (n = 766)
Undetectable VL

400

52.2

CD4 Cell Count (n = 593)
Baseline count ≤ 200

51

8.6

Baseline count > 200

542

91.4

Diagnosed with substance abuse

99

12.2

Not diagnosed with substance abuse

714

87.8

Baltimore

90

11.1

Birmingham

61

7.5

Los Angeles

84

10.3

Memphis

187

23.0

San Diego

101

12.4

Tampa

219

26.9

Washington DC

71

8.7

Substance Abuse Diagnosis

ATN Clinical Site

M

SD

Age (Range: 14 - 26; Mdn. = 21)

21

2.6

BMI (Range: 4.8 - 69.5; Mdn. = 23.3; n = 806)

25

6.7

0.062

0.040

Cardiac Risk Score1* (Range: 0.01 - 0.26; Mdn. = 0.061)

Cardiac Risk Score2** (Range: 0.17 - 4.05; Mdn. = 0.569; n = 398)
0.672 0.401
*Cardiac Risk Score1: Defined as the risk score for patients with systolic blood pressure,
smoking, diabetes, and anti-hypertensive medication use.
**Cardiac Risk Score2: Defined as the risk score for patients with systolic blood pressure,
smoking, diabetes, anti-hypertensive medication use, total cholesterol, and HDL.
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Table 3. Bivariate Analysis by Detectable VL
Total Sample

Detectable VL

Undetectable VL

N = 766

n = 366

n = 400

Test Statistics

n

%

n

%

n

%

df

χ²

Black

539

70.5

271

74.5

268

67.0

3

9.881*

Latino

85

11.1

43

11.8

42

10.5

White

73

9.6

27

7.4

46

11.5

Other

67

8.8

23

6.3

44

11.0

Male

527

68.8

266

72.7

261

65.2

1

4.912*

Female

239

31.2

100

27.3

139

34.8

Currently on ART medication

691

90.2

321

87.7

370

92.5

1

4.975*

Not reportedly on ART medication

75

9.8

45

12.3

30

7.5

Baseline count ≤ 200

50

8.6

42

15.8

8

2.5

1

32.326***

Baseline count > 200

532

91.4

224

84.2

308

97.5

Diagnosed with substance abuse

97

12.7

49

13.4

48

12.0

1

0.333

Not diagnosed with substance abuse

669

87.3

317

86.6

352

88.0

Race/Ethnicity (n = 764)

Gender

ART Medication

CD4 Cell Count (n = 593)

Substance Abuse Diagnosis

M

SD

M

SD

M

SD

df

F

Age

21

2.6

21

2.5

21

2.7

764

2.990

BMI (n = 762)

25

6.8

25

6.6

26

6.9

760

3.626

Cardiac Risk Score1

0.062

0.040

0.067

0.042

0.058

0.037

764

2.049***

Cardiac Risk Score2 (n = 394)

0.672

0.672

0.735

0.452

0.626

0.348

392

4.577**

Note: *p <0.05. ** p <0.01. ***p <0.001.
Cardiac Risk Score1: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, and anti-hypertensive medication use.
Cardiac Risk Score2: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, anti-hypertensive medication use, total cholesterol, and HDL.
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Table 4. Bivariate Analysis by Low CD4 Cell Count
Total Sample

CD4 Cell Count ≤ 200

CD4 Cell Count > 200

N = 593

n = 51

n = 542

Test Statistics

n

%

n

%

n

%

df

χ²

Black

431

72.9

44

88.0

387

71.5

3

6.548

Latino

63

10.7

3

6.0

60

11.1

White

48

8.1

1

2.0

47

8.7

Other

49

8.3

2

4.0

47

8.7

Male

420

70.8

36

70.6

384

70.8

1

0.002

Female

173

29.2

15

29.4

158

29.2

Currently on ART medication

529

89.2

48

94.1

481

88.7

1

1.397

Not reportedly on ART medication

64

10.8

3

5.9

61

11.3

Detectable VL

266

45.7

42

84.0

224

42.1

1

32.326***

Undetectable VL

316

54.3

224

42.1

308

57.9

Diagnosed with substance abuse

86

14.5

9

17.6

77

14.2

1

0.445

Not diagnosed with substance abuse

507

85.5

42

82.4

465

85.8

Race/Ethnicity (n = 591)

Gender

ART Medication

Viral Load (n = 582)

Substance Abuse Diagnosis

M

SD

M

SD

M

SD

df

F

Age

21

2.6

21

2.5

21

2.5

591

0.042

BMI (n = 591)

25

6.8

24

5.8

25

7.0

589

3.357

Cardiac Risk Score1

0.062

0.039

0.066

0.046

0.060

0.037

591

1.223

Cardiac Risk Score2 (n = 343)

0.672

0.401

0.864

0.741

0.621

0.338

341

8.712**

Note: *p <0.05. ** p <0.01. ***p <0.001.
Cardiac Risk Score1: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, and anti-hypertensive medication use.
Cardiac Risk Score2: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, anti-hypertensive medication use, total
cholesterol, and HDL.
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Table 5. Multivariable Linear Regression Models by Cardiac Risk Scores
Model 1 with Cardiac Risk Score1
Model 1A with VL Results
Unstandardized
Standardized

Model 1B with CD4 Results
Unstandardized
Standardized

Model 1C with VL and CD4 Results
Unstandardized
Standardized

B

SE

95% CI

β

B

SE

95% CI

β

B

SE

95% CI

β

Age
Race/Ethnicity
Gender

0.001
0.002
0.061

0.000
0.001
0.002

(0.000, 0.002)
(0.000, 0.004)
(0.057, 0.065)

0.072**
0.056*
0.710***

0.000
0.001
0.002

(0.001, 0.003)
(0.000, 0.004)
(0.053, 0.063)

0.123***
0.043
0.691***

0.002
0.001
0.059

0.000
0.001
0.003

(0.001, 0.003)
(-0.001, 0.004)
(0.054, 0.064)

0.135***
0.036
0.696***

ART Medication
Substance Abuse Diagnosis
BMI
Viral Load
CD4 Cell Count

0.001
0.015
0.000
0.002
---

0.003
0.003
0.000
0.001
---

(-0.005, 0.008)
(0.009, 0.020)
(0.000, 0.001)
(0.000, 0.003)
---

0.010
0.124***
0.057*
0.067**
---

0.002
0.002
0.058
0.001
0.017
0.000
--0.000

0.003
0.003
0.000
--0.000

(-0.008, 0.006)
(0.011, 0.023)
(0.000, 0.001)
--(-0.001, 0.000)

-0.007
0.159***
0.055
---0.028

0.001
0.015
0.000
0.002
0.000

0.004
0.003
0.000
0.001
0.000

(-0.006, 0.008)
(0.008, 0.021)
(0.000, 0.001)
(0.001, 0.004)
(-0.001, 0.001)

0.006
0.136***
0.053
0.088**
0.015

Note: *p <0.05. ** p <0.01. ***p <0.001.
Model 2 with Cardiac Risk Score2
Model 2A with VL Results
Unstandardized
Standardized
Age
Race/Ethnicity
Gender
ART Medication
Substance Abuse Diagnosis
BMI
Viral Load
CD4 Cell Count

Model 2B with CD4 Results
Unstandardized
Standardized

Model 2C with VL and CD4 Results
Unstandardized
Standardized

B

SE

95% CI

β

B

SE

95% CI

β

B

SE

95% CI

β

0.012
0.039
0.164
0.030
0.059
0.014
0.038

0.008
0.021
0.044

(-0.003, 0.027)
(-0.002, 0.081)
(0.077, 0.251)

0.081
0.091
0.188***

0.008
0.022
0.045

(0.007, 0.039)
(-0.002, 0.082)
(0.074, 0.252)

0.152**
0.096
0.194***

(0.008, 0.040)
(0.002, 0.088)
(0.080, 0.259)

0.158**
0.105*
0.201***

(-0.174, 0.114)
(-0.049, 0.166)
(0.008, 0.019)
(0.011, 0.066)

-0.020
0.053
0.245***
0.134**

0.070
0.054
0.003
---

(-0.218, 0.057)
(-0.032, 0.180)
(0.007, 0.018)
---

-0.059
0.071
0.236***
---

0.071
0.054
0.003
0.016

(-0.209, 0.070)
(-0.053, 0.162)
(0.007, 0.018)
(0.009, 0.071)

-0.050
0.053
0.240***
0.146*

---

---

---

---

0.007

(-0.025, 0.001)

-0.095

0.024
0.045
0.170
0.069
0.055
0.013
0.040
0.005

0.008
0.022
0.046

0.073
0.055
0.003
0.014

0.023
0.040
0.163
0.080
0.074
0.013
--0.012

0.007

(-0.019, 0.010)

-0.035

Note: *p <0.05. ** p <0.01. ***p <0.001.
Cardiac Risk Score1: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, and anti-hypertensive medication use.
Cardiac Risk Score2: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, anti-hypertensive medication use, total cholesterol, and HDL.
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CHAPTER 3 - Cigarette smoking and metabolic syndrome in youth
living with HIV: Findings from electronic health records in the
United States
Abstract
Background: Detectable viral load (VL) has been found to be associated with cardiovascular
disease (CVD) and smoking among HIV-positive population. A recent study reported 20.4% of
youth living with HIV (YLH) smoking cigarette daily or almost daily, and observed significance
of cigarette smoking with higher mean log 10 VL. Metabolic changes leading to the development
of atherosclerosis can start early in life, but are often undiagnosed in their early stages. Metabolic
syndrome is a growing concern that may surpass smoking as one of the leading risk factors of
CVD. We examined the association of smoking and metabolic syndrome with VL in YLH aged
14-26y.
Methods: The data for this study were drawn from the Adolescent Medicine Trials Network 154
Cascade Monitoring Protocol. De-identified electronic health records of YLH who received care
in 2016 were extracted from multidisciplinary adolescent HIV clinics across the United States.
This study utilized a subsample of 398 YLH. Multivariable logistic regression was used to
examine whether smoking and components of metabolic syndrome are related to a greater
likelihood of high VL.
Results: Our sample included a higher proportion of Black youth (76.8%) and males (69.6%)
with mean age of 21y. Overall, 44.4% had a detectable VL, 26.9% were cigarette smokers based
on ICD-10 diagnoses of tobacco dependence, and 27.6% met the criteria for metabolic
syndrome. In bivariate analyses, among those who smoked cigarette compared to those who did
not smoke, we observed a significantly greater proportion of patients with detectable VL (54.7%
52

vs. 40.6%; p < 0.05). Similarly, among those who had low HDL cholesterol compared to those
who had ideal HDL, we observed a significantly greater proportion of patients with detectable
VL (54.9% vs. 37.1%; p < 0.001). In multivariable analyses, after adjusting for demographic and
clinical differences, the odds of having detectable VL among those who smoked cigarette is
2.051 times that of those who did not smoke (AOR = 2.051; 95% CI = 1.101, 3.823; p < 0.05).
However, no significant differences (p > 0.05) were observed in the components of metabolic
syndrome on VL.
Conclusions: We observed positive association between smoking and VL non-suppression,
highlighting the importance of smoking cessation in viral suppression and in reducing the overall
burden of CVD risk in YLH. Our findings of greater prevalence of metabolic syndrome suggests
routine monitoring of metabolic risks in YLH.

Keyword(s): Smoking, metabolic syndrome, viral load, cardiovascular risk, youth living with
HIV
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Introduction
Cardiovascular disease (CVD) is the leading cause of death in the United States (U.S.)
and prevalence of high-risk individuals is prominent for non-Hispanic Black males.1 Despite
advances in the identification of risk factors for CVD and the widespread use of evidence-based
strategies to manage CVD, overall cardiovascular health is lowest in Black Americans than nonHispanic Whites, and CVD mortality is higher in Black Americans than White counterparts.2
Since treatments for HIV have become more effective, research has shifted focus from the more
acute symptoms onto the chronic comorbid conditions such as CVD.3,4
According to the current guidelines, antiretroviral therapy (ART) is initiated immediately
after diagnosis in youth and young adults5 however, youth and young adults are underrepresented
in research on HIV and its connections to CVD. Cardiovascular health assessment practices and
public health strategies for those young adults living with HIV and the younger populations atrisk for HIV are few and far between and this lack of knowledge could pose significant problems
as these generations grow older.
Prior studies, including chapter 2 of the dissertation, have found that detectable viral load
is associated with cardiovascular risk6,7 and smoking among HIV-positive populations in the
U.S.8,9 Rates of tobacco use have been 40% of people with HIV10-13 and significantly more
common compared to the general population.14-16 Among youth living with HIV (YLH), in
particular, tobacco use has been reported to be 32.9-38.7% in two cross-sectional nationwide
cohort studies recruited through the Adolescent Medicine Trials Network for HIV/AIDS
Interventions (ATN).17,18 More recently, Gamarel and colleagues reported 20.4% of YLH
smoking cigarettes daily or almost daily, and showed tobacco smoking predicting viral
suppression, reinforcing the need for smoking cessation interventions and preventive services in
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this population.19 Given that viral suppression fluctuates20 and tobacco use significantly predicts
viral load (VL) levels, new screening tools and clinical and self-management approaches need to
be explored and utilized, especially among YLH.
Although smoking is one of the primary preventable causes of CVD, metabolic syndrome
is a growing concern that may surpass smoking as one of the leading risk factors for CVD.21
Metabolic syndrome is the clustering of any three of a group of five conditions that elevate risk
of heart disease and diabetes: high blood pressure, high blood glucose, high triglycerides, low
HDL cholesterol, and increased abdominal fat.22-24 The links among smoking, metabolic
syndrome, and CVD in HIV-positive populations remain unclear. Although one study has found
little association between cigarette smoking and metabolic risk factors among YLH,18 other
studies have found tobacco use generally to be related to increased dyslipidemia, blood glucose
processing, and metabolic syndrome, particularly with high triglycerides and low HDL
cholesterol levels.25-29 In addition, although some studies have not found metabolic syndrome to
be more prevalent in the HIV-positive population compared to the general population,30 other
studies have shown that metabolic risk factors are indeed prevalent in the HIV-positive
population,31-34 including YLH,35 and are independently associated with VL.32
Being overweight and obese are themselves risk factors for CVD morbidity and
mortality,36 and they are often associated with the development of CVD risk factors during
adolescence.37 Data from the National Health and Nutrition Examination Survey provided the
most recent national estimates from 2015-2016 on obesity and the prevalence of obesity was
higher among U.S. adolescents aged 12-19 years (20.6%) compared with children aged 2-5 years
(13.9%).38 Most importantly, adult adiposity is an established risk factor for developing adult
CVD and there is evidence suggesting that overweight adolescents have a 40%-80% chance of
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becoming overweight or obese adults.37 Despite the high prevalence of adolescent obesity and
adult CVD, being overweight and obese has been studied less extensively within the HIVpositive population.36 Although ART decreases the risk of HIV-specific morbidity and mortality,
U.S.-based studies found that patients on ART experience an increase in body mass index
(BMI),39,40 highlighting the importance of maintaining health body weight in adolescents
initiating early ART.
Given the increasing prevalence of obesity among American youth41 and that more than
half of youth have been shown to have at least one CVD risk factor,42 there is an urgent need to
better understand the relationship among metabolic risk factors, smoking, and CVD risk among
YLH, a high-risk and underserved population. The current study leveraged the electronic health
records (EHR) of a multi-site clinical sample of YLH in the U.S. to examine whether smoking
and metabolic syndrome were associated with VL.

Methods
Study Design and Population
The data for this study were drawn from the ATN Cascade Monitoring Study, one of the
protocols of ATN’s Scale It Up initiative.43 De-identified EHR were requested from ten
participating sites for the baseline year between January 1, 2016 and December 31, 2016 as
described previously.44 To be included in these analyses, data on a patient’s age, race, ethnicity,
gender, height, weight, CD4 cell count results, VL results, systolic blood pressure, cholesterol
panel, blood pressure medications, ART medications, and the International Statistical
Classification of Disease and Related Health Problems Tenth Revision (ICD-10) diagnosis codes
for diabetes, cigarette smoking, alcohol and drugs were required. Because Brooklyn, Miami,
Philadelphia, and San Diego did not provide gender, systolic blood pressure, and cholesterol
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data, these four sites were excluded from further analyses (see Table 1). The Institutional Review
Boards of both Florida State University and the City University of New York approved to
conduct analyses of de-identified data.
Measures
Demographics. We defined age as a continuous variable in years as reported by site.
Gender, race, and ethnicity definitions varied within a site’s data. These demographic variables
were constructed as reported by site. For gender we constructed a binary variable of male vs.
female. Race/ethnicity was categorized into Black, Latino, White, Hispanic or Other. Missing
race for one patient was kept as missing data and removed from these analyses.
HIV and immunologic biomarkers. Earliest date reported VL values in “copies/mL” by
site were used. VL threshold detectability was coded as binary. Missing VL results for four
patients were not included in these analyses. Based on the guidelines for the Use of
Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, we defined
immunocompromised state as CD4 T lymphocyte cell count of less than or equal to 200.5,45 We
created a binary variable of CD4 cell count with “baseline count ≤ 200” and “baseline count
>200.” CD4 cell count, a measure of immune status, was missing for 13.8% (n = 55) of the
sample and thus excluded from this analysis.
ART medication. All prescribed HIV medications were coded into a dichotomous variable
where 0 = no prescribed medication and 1 = at least one prescribed medication. Missing values
were assumed to be the result of no prescription by doctors and were recoded into the category of
non-ART medication.
Substance abuse diagnosis: We used ICD-10 codes F1010, F1210, F1220, F1290, F1510,
F1511, F1520, F1590, F17200, F17210, F1910, and F1920 to identify alcohol and drugs such as
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amphetamines, cannabis, cocaine, hallucinogens, and opioids. A dichotomous variable was
created for patients having any vs. no substance abuse. Missing values were coded as no
substance abuse.
BMI. We used BMI, a measure of weight relative to height (kg/m2), as a proxy of
adiposity. Tallest and earliest reported value for height and highest and earliest reported value for
weight were used. Patients (n = 7) with missing values were removed from further analyses. We
defined obesity as BMI ≥ 30 for patients who were between 21 and 26.46 For those who were
between 14 and 20, obesity was defined as BMI for age and sex at or above the 95th percentile
using the CDC growth chart.22,24,47
Cigarette smoking. We used ICD-10 codes F17200 and F17210 for tobacco use. If these
codes were missing, we pulled data from patient self-report such as current status and never
smoked at each site. A dichotomous variable for smoking was created.
Hypertension medication. A dichotomous variable was created, including the presence of
any site-reported prescriptions including amlodipine, enalapril, lisinopril, and spironolactone.
Hypertension. Since our target population was YLH, only systolic blood pressure as
reported by site was used. Hypertension was defined as systolic blood pressure ≥ 130 mmHg or
treatment with anti-hypertensive medication.22-24
Hyperglycemia. We used ICD-10 codes E10XX, E11XX or E13XX for diagnosis of
diabetes. Patients without these ICD-10 diagnosis codes were given a missing value for diabetes
and evaluated for predetermined criteria i.e. blood glucose HbA1c results > 6.0 mmol/L or
fasting blood glucose of > 110 mg/dL or random blood glucose of > 180. We included diabetes
diagnosis in addition to glucose measures for creating a dichotomous variable for hyperglycemia.
We coded as hyperglycemia for patients reported to have diabetes or blood test results exceeded
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predetermined criteria. Missing values for diabetes and those who did not meet predetermined
criteria were coded as no hyperglycemia.
Triglycerides and HDL cholesterol. We defined hypertriglyceridemia as the fasting blood
triglyceride levels ≥150 mg/dL.24 For low HDL cholesterol, < 45 mg/dL was used for boys and
girls aged 19y or younger,48 while ≤ 40 mg/dL and <50 mg/dL were used for men and women
aged 20y or older, respectively.48
Metabolic syndrome. Metabolic syndrome comprises obesity, hypertriglyceridemia, low
HDL cholesterol level, hypertension, and hyperglycemia.21 We constructed a categorical variable
for metabolic syndrome with three categories: 0-1 component, 2 components, and 3 or more
components.22-24 Patients with 3 or more components were considered to meet diagnostic criteria
for metabolic syndrome.22-24
Data Analysis
For this study, we focused on a subset of patients (n = 398) from the baseline analytic
sample of 813 EHRs collected in 2016 in order to incorporate routinely obtained laboratory data
(glucose, triglycerides, and HDL cholesterol). To examine the prevalence of cigarette smoking
and metabolic syndrome, we divided the study sample into two groups based on VL status. First,
we performed a descriptive analysis of demographic and clinical characteristics of the sample.
Second, we conducted bivariate analyses of the relationships along smoking, metabolic
syndrome, and VL using chi-square and independent samples t-tests. Finally, we ran a series of
three multivariable logistic regression models and examined the associations of smoking and
components of metabolic syndrome with detectable VL as a dichotomous outcome variable. The
first model was constructed to test the hypothesized positive association of smoking on
detectable VL. The second model was constructed to test the hypothesized positive association of
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metabolic syndrome on detectable VL. The third model was constructed to test the hypothesized
positive associations of smoking and metabolic syndrome on detectable VL. Covariates included
in the models were the required demographic variables – age, race/ethnicity, and gender. We also
adjusted for the ue of ART medication, substance dependence, and CD4 cell count. All analyses
were performed in IBM SPSS Statistics 25 and syntax files were developed to construct new
variables and recode some variables based on the analytic design. The threshold for statistical
significance was 0.05.

Results
Demographic and clinical characteristics of the analytic sample (n = 398) are displayed in
Table 2. The mean age was 21y with a range of 14 to 26 years (SD = 2.7). The majority of the
patients identified as Black (76.8%) followed by Other (10.6%), White (6.8%), and Latino
(5.8%). More than half (69.6%) of the sample were male. The mean VL, a measure of ART
adherence was 22,440 (SD = 93,965.4). Nearly half (44.4%) had a detectable VL. Among those
with a detectable VL, 29.9% had > 1000 copies/mL. The mean CD4 cell count was 633 (SD =
302.3). Among those with a CD4 cell count value available, 7.3% had a baseline count of ≤ 200
indicating immunocompromised status.
Among those sites with the required data for this study, Memphis had the largest sample
size (n = 157; 39.4%). The mean BMI was 25 kg/m2 with a range of 4.8 to 69.5 (SD = 6.7) and
the mean systolic blood pressure was 129 mmHg with a range of 92 to 180 (SD = 11.7). Of the
398 YLH, 92.2% were currently prescribed ART; 15.6% were diagnosed with substance abuse;
26.9% were smokers; 15.1% were obese; 52% had hypertension; 7.8% were hyperglycemic;
15.4% had hypertriglyceridemia; and 40.7% had low HDL cholesterol level. The proportion of
patients who met the criteria for each of the three categories of the metabolic syndrome is shown
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in Figure 1. More than one-quarter (27.6%) of YLH had metabolic syndrome. Among male
patients, 23.8% had two components of metabolic syndrome and 28.5% met the definition of
metabolic syndrome. Among female patients, 26.4% had two components of metabolic
syndrome and 25.6% met the definition of metabolic syndrome.
Bivariate correlates across demographic and clinical variables
Smoking vs. nonsmoking groups. The associations between demographic and clinical
variables of interest are displayed in Table 3. The chi-square tests performed to compare the
differences in detectable and undetectable VL for cigarette smoking status and CD4 cell count
were statistically significant. Among those who smoked cigarette compared to those who did not
smoke, we observed a significantly greater proportion of patients with detectable VL (54.7% vs.
40.6%; p < 0.05). Among those who had CD4 cell count ≤ 200 compared to those who had CD4
cell count > 200, we observed a significantly greater proportion of patients with detectable VL
(84.0% vs. 41.0%; p < 0.001). No significant differences (p > 0.05) were found in race/ethnicity,
gender, ART medication, substance abuse diagnosis, hypertension medication, age, BMI, and
systolic blood pressure.
Clinical correlates of metabolic syndrome. The associations between the components of
metabolic syndrome and VL are displayed in Table 4. Among those who had low HDL
cholesterol compared to those who had ideal HDL, we observed a significantly greater
proportion of patients with detectable VL (54.9% vs. 37.1%; p < 0.001). However, no significant
differences (p > 0.05) were observed in other components of metabolic syndrome on VL when
comparing patients who met the criteria for metabolic syndrome.
Multivariable correlates of VL
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Cigarette smoking and metabolic syndrome. Multivariable logistic regression analysis of
VL from demographic and clinical characteristics including smoking and metabolic syndrome is
shown in a series of models in Table 5. Model 1 presents the association of cigarette smoking on
VL. After adjusting for demographic and clinical differences, patients who smoked cigarette
compared to those who did not smoke were significantly more likely to have detectable VL
(AOR = 2.051; 95% CI = 1.101, 3.823; p < 0.05). This indicates that the odds of having
detectable VL among those who smoked cigarette is 2.051 times that of those who did not
smoke.
Model 2 presents the association of the components of metabolic syndrome on VL. After
adjusting for demographic and clinical differences, patients who had 2 components of metabolic
syndrome compared to those who had 0-1 component of metabolic syndrome were marginally
significant with detectable VL (AOR = 0.365; 95% CI = 0.818, 2.536; p = 0.052). Model 3
presents the association of smoking and metabolic syndrome together on VL. After adjusting for
demographic and clinical differences, patients who smoked cigarette compared to those who did
not smoke were significantly more likely to have detectable VL (AOR = 2.038; 95% CL = 1.090,
3.811; p < 0.05). This indicates that the odds of having detectable VL among those who smoked
cigarette is 2.038 times that of those who did not smoke. Patients who had 2 components of
metabolic syndrome was marginally significant with detectable VL (AOR = 0.360; 95% CI =
0.811, 2.532; p = 0.056).
Discussion

The purpose of this study was to examine whether smoking and metabolic syndrome
were associated with VL among YLH aged 14-26y in the U.S. In a clinic-based sample of
predominantly Black YLH, nearly half (44.4%) had a detectable VL, 26.9% were smokers, and
27.6% met the definition of metabolic syndrome. The estimated proportion achieving viral
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suppression is lower than the U.S. estimates of 53.8% among persons aged 13-24 years.49 Our
study had a lower prevalence of cigarette smoking than previously reported in two ATN cohort
studies among YLH (32.9-38.7%).18 Prevalence estimates for the metabolic syndrome may vary
based on the criteria used; nevertheless, our study found a higher prevalence of metabolic
syndrome compared to a more recent study of 80 HIV-positive adolescents (aged 14.6-18y,
10%).50
Our findings support the hypothesis that smoking is positively associated with detectable
VL after adjusting for potential confounding variables, highlighting the importance of linking
smoking prevention and HIV care in routine clinical practice. These findings are consistent with
a recent study of YLH engaged in HIV care in one of the ATN clinical sites or affiliates that also
observed a significant association between tobacco use and decreased odds of sustained viral
suppression.19 Although studies in adults provide evidence that cigarette smoking is associated
with HIV prognosis,8,9,51 the potential mechanisms underlying the effect of smoking on HIV are
unclear. As indicated by previous studies,51-53 smoking may cause or promote higher VL via
various mechanisms, including oxidative stress and induction of the cytochrome P450 (CYP)
pathway. More specifically, the CYP1A1-m1 polymorphism, which is associated with greater
enzymatic activity, can increase VL through conversion of toxins found in cigarette smoke into
DNA adducts, which may directly promote HIV-1 gene expression.51,53 Therefore, we
hypothesized that higher oxidative stress may be a common mechanism underlying the
pathophysiological process of increased odds of detectable VL being associated with smoking.
However, the detailed mechanism on the potential biological effect of smoking on VL should be
further studied.
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After adjusting for potential confounding variables, we did not observe any statistically
significant independent associations between the different components of metabolic syndrome
and detectable VL among YLH. This finding points to increased prevalence of cardiometabolic
risk factors and suggests clinical treatments are for the individual components, not metabolic
syndrome as a whole. The framework of metabolic syndrome is a convenient tool used to
understand the effects of insulin resistance on human physiology in populations studies24 but
ultimately carries little clinical meaning beyond its individual components. Although
pediatricians can use metabolic syndrome as an organizing framework, the focus for clinical
screening and treatment should be on obesity, glucose abnormalities, hypertension, and
dyslipidemia.24 Using EHR might be a useful strategy to incorporate screening tools and help
medical providers to identify at-risk patients and provide guidance on prevention and
management of metabolic dysfunction. This in turn could prevent or delay the onset of CVD.
Atherosclerosis, the pathological process that involves inappropriate lipid metabolism
and activation of the innate and adaptive immune systems in the arterial wall,54,55 accelerates
during adolescence. CVD risk in youth aged 18 to 24 years is underestimated despite the high
prevalence of CVD risk factors56-59 and early signs of atherosclerosis in this group.60,61
Adolescence and young adulthood are critical developmental phases and can have a significant
impact on cardiovascular health.62 Obesity has more than tripled in youth over the past 30
years.41 CVD risk increases by 2-4% for each year a youth is obese.63 As many as 33% of
adolescents are overweight,57 and this excess weight leads to dyslipidemia64 and increases in
metabolic syndrome,65 diabetes,66 and CVD59 risk. CVD contributes to half of CVD deaths and is
one of the leading causes of death in adolescents.67 More than half of youth in the U.S. have at
least one CVD risk factor, and this directly affects cardiovascular health throughout the
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lifespan.42 Adolescence is the key age because many CVD risk factors surface in adolescence67-70
and track into adulthood.71 The AHA’s 2020 Strategic Impact Goals along with the National
Heart, Lung, and Blood Institute’s (NHLBI) 2012 Expert Panel on Integrated Guidelines for
Cardiovascular Health and Risk Reduction in Adolescents72 emphasize early prevention in
adolescence42 to prevent the development of CVD later in life and help curtail the high costs.
Our study sample had a disproportionately higher proportion of Black YLH and
identified as male gender. Studies have demonstrated the high burden of CVD especially related
to mortality in Black men and the high burden of HIV among Black youth in the U.S. A recent
study analyzed the U.S. nationally representative data by calculating the CVD risk score
developed in 2013 by the American Heart Association (AHA) and the American College of
Cardiology and found that prevalence among non-Hispanic Black males increased significantly
from 53% in 1999-2002 to 65.2% in 2011-2014 using the 7.5% 10-year risk cut off (p = 0.003).1
The Centers for Disease Control and Prevention (CDC) reported continued trend of HIV
infections among youth of color, Black and Latino representing 54% and 25% of new HIV
diagnoses, respectively, compared to those who identified as White and Other, accounting for
16% and 5% of new HIV diagnoses in 2016.73 Targeting HIV and CVD prevention, specifically
in racial and ethnic minority populations of youth who are unaware of their risk of CVD, in a
coordinated manner has important clinical implications. The earlier screening and treatment
plans begin, the less risk these individuals have of developing metabolic syndrome, thus
reducing their risk of CVD and mortality.
The AHA’s “seven metrics” have been created to educate the public on healthy lifestyle
habits to ensure ideal cardiovascular health.74 These seven metrics define what cardiovascular
health is and help us to prevent CVD in the future. The defining characteristics of cardiovascular
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health include “non-smoking status or having quit more than 1 year ago, BMI < 25 kg/m2, ≥ 150
minutes per week of physical activity, health dietary pattern (high in fruits and vegetables, fish,
and fiber-rich whole grains, low in sodium and sugar-sweetened beverages), total cholesterol <
200 mg/dL, blood pressure < 120/80 mm/Hg, and fasting blood glucose < 100 mg/dL.”75 To
summarize, a healthy lifestyle means a healthy heart. By focusing on decreasing health
inequalities linked to impoverished areas and social minorities as well as defining easy steps to
educate those who otherwise might have made unhealthy choices will, through prevention,
decrease the strain that CVD has on the health system and on public health in general. However,
there is an increased risk of CVD within the HIV-positive community that needs to be addressed.
Although these “seven metrics” can be helpful preventing CVD in HIV-positive individuals in
the same way as they are in the general population, the metrics doesn’t cover risks that only
pertain to those who live with HIV and can’t be prevented, such as the side effects of ART and
the impact HIV itself has on the cardiovascular health. The lack of studies on the “seven metrics”
for cardiovascular health among YLH is a problem and further research on this link must be
investigated.
This study has some limitations. First, the study design was cross-sectional so no
causality could be inferred. Our clinic-based sample may also limit the generalizability of our
findings to the entire YLH population in the U.S. Second, the lack of smoking data within the
EHR on how much (number of packs per day) and how long (number of years) limited the study
from assessing the association of quantity and duration of smoking with VL. A large multicenter
prospective study with long-term follow-up should be implemented in the future to identify
trajectories of smoking over time. Third, the cross-sectional study design does not provide
evidence regarding the potential mechanism of the association of smoking and 2 components of
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metabolic syndrome on VL. Future research needs to focus on the pathways and test the
mediation effects of higher oxidative stress as the pathophysiological process of higher plasma
VL associated with smoking. Fourth, the present study did not examine the combined effect of
smoking and metabolic syndrome on VL. Future investigation is needed to further assess the
synergistic effect of smoking and the components of metabolic syndrome on VL. Fifth, we used
BMI as the metric to define obesity clinically because of lack of data on body composition and
body fat distribution, which are more precise indicators of metabolic and cardiovascular risk.
Finally, although regression was used for adjusting confounders, residual confounders cannot be
avoided and it can bias the association in any direction (towards or away from the null). Despite
these limitations, our results provide an opportunity to capitalize on the potential long-term
benefits of routinely collected EHR data for public health surveillance.
The present study indicates that cigarette smoking is positively associated with increased
odds of having detectable VL in YLH, while the presence of different components of metabolic
syndrome was not observed to be significantly associated, and these observations supplement the
existing knowledge on the relationship among smoking, metabolic syndrome, and VL.
Furthermore, this study highlights the need for more research in diverse population cohorts of
YLH in order to gain additional insights into any disparities in the relationship of HIV with
cardiometabolic risk factors in Black YLH compared with other racial/ethnic groups. Overall,
more routine metabolic monitoring is key to improve the cardiovascular health of YLH. Smoking
prevention intervention platform integrated with EHR as well as effective implementation of
evidence-based guidelines could improve cardiovascular health and lower cardiometabolic risk
in YLH.
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Table 1. Data Sources
City
Baltimore
Birmingham
Los Angeles
Memphis
Tampa
Washington DC
Total

n
72
44
67
157
54
4
398

%
18.1
11.1
16.8
39.4
13.6
1.0
100.0
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Table 2. Demographic and Clinical Characteristics of the Sample (N = 398)
Race/Ethnicity (n = 397)
Black
Latino
White
Other
Gender
Male
Female
ART Medication
Currently on ART medication
Not reportedly on ART medication
Viral Load (n = 394)
Detectable VL
Undetectable VL
CD4 Cell Count (n = 343)
Baseline count ≤ 200
Baseline count > 200
Substance Abuse Diagnosis
Diagnosed with substance abuse
Not diagnosed with substance abuse
Cigarette Smoking Status
Smoking
Nonsmoking
Hypertension Medication
Currently on hypertension medication
Not reportedly on hypertension medication
Obesity
Yes
No
Hypertension
Yes
No
Hypertriglyceridemia (n = 395)
Yes
No
Low HDL Cholesterol
Yes
No
Hyperglycemia
Yes
No

Age (Range: 14 - 26; Mdn. = 21)
BMI (Range: 4.8 - 69.5; Mdn. = 23.5)
Systolic Blood Pressure (Range: 92 - 180; Mdn. = 130)
ART antiretroviral therapy, BMI body mass index, HDL high-density lipoprotein

n

%

305
23
27
42

76.8
5.8
6.8
10.6

277
121

69.6
30.4

367
31

92.2
7.8

175
219

44.4
55.6

25
318

7.3
92.7

62
336

15.6
84.4

107
291

26.9
73.1

4
394

1.0
99.0

60
338

15.1
84.9

207
191

52.0
48.0

61
334

15.4
84.6

162
236

40.7
59.3

31
367

7.8
92.2

M
21
26
129

SD
2.7
7.1
11.7
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Figure 1. Metabolic syndrome among a clinic-based sample of YLH aged 14-26 in the
United States (n = 398)

Proportion of Patients

Metabolic Syndrome
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110
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23.8
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47.9

n

%

n

%

n

%

Total

Male

Female

0-1 Components

2 Components

≥3 Components
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Table 3. Bivariate Association with Cigarette Smoking Status and VL
Total
Sample
N = 394
n
%
Race/Ethnicity (n = 393)
Black
Latino
White
Other
Gender
Male
Female
ART Medication
Currently on ART medication
Not reportedly on ART medication
Cigarette Smoking Status
Smoking
Nonsmoking
CD4 Cell Count (n = 340)
Baseline count ≤ 200
Baseline count > 200
Substance Abuse Diagnosis
Diagnosed with substance abuse
Not diagnosed with substance abuse
Hypertension Medication
Currently on hypertension medication
Not reportedly on hypertension medication

Age
BMI
Systolic Blood Pressure
Note: *p < 0.05. ** p < 0.01. ***p < 0.001.
ART antiretroviral therapy, BMI body mass index, VL viral load

Detectable VL
n = 175
n
%

Undetectable VL
n = 219
n
%

Test Statistics
df
χ²

301
23
27
42

76.6
5.9
6.9
10.7

142
10
8
14

81.6
5.7
4.6
8.0

159
13
19
28

72.6
5.9
8.7
12.8

3

5.418

275
119

69.8
30.2

124
51

70.9
29.1

151
68

68.9
31.1

1

0.168

363
31

92.1
7.9

159
16

90.9
9.1

204
15

93.2
6.8

1

0.706

106
288

26.9
73.1

58
117

33.1
66.9

48
171

21.9
78.1

1

6.232*

25
315

7.4
92.6

21
129

14
86

4
186

2.1
97.9

1

17.409***

62
332

15.7
84.3

30
145

17.1
82.9

32
187

14.6
85.4

1

0.47

4
390

1.0
99.0

2
173

1.1
98.9

2
217

0.9
99.1

1

0.051

M
21
25.6
129

SD
2.7
7.1
11.7

M
21
25.4
130

SD
2.7
7.4
12.3

M
21
25.7
129

SD
2.6
6.9
11.1

df
392
392
392

F
1.250
0.033
0.248

75

Table 4. Bivariate Association with Metabolic Syndrome and VL
Total Sample
N = 394
n
%
Obesity
Yes
60
No
334
Hypertension
Yes
207
No
187
Hypertriglyceridemia (n = 391)
Yes
61
No
330
Low HDL Cholesterol
Yes
162
No
232
Hyperglycemia
Yes
31
No
363
Metabolic Syndrome
0-1 Components indicated
187
2 Components indicated
97
≥3 Components indicated
110
Note: *p < 0.05. ** p < 0.01. ***p < 0.001.
HDL high-density lipoprotein, VL viral load

Detectable VL
n = 175
n
%

Undetectable VL
n = 219
n
%

Test Statistics
df
χ²

15.2
84.8

21
154

12.0
88.0

39
180

17.8
82.2

1

2.542

52.5
47.5

95
80

54.3
45.7

112
107

51.1
48.9

1

0.386

15.6
84.4

24
149

13.9
86.1

37
181

17.0
83.0

1

0.704

41.1
58.9

89
86

50.9
49.1

73
146

33.3
66.7

1

12.338***

7.9
92.1

17
158

9.7
90.3

14
205

6.4
93.6

1

1.480

47.5
24.6
27.9

75
50
50

42.9
28.6
28.6

112
47
60

51.1
21.5
27.4

2

3.452
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Table 5. Multivariable Logistic Regression Models by VL
Model 1: Smoking with
Detectable VL
Age
Race/Ethnicity (Ref: White)
Black
Latino
Other
Gender (Ref: Female)
Male
ART Medication (Ref: Not on ART)
Currently on ART medication
Substance Abuse Diagnosis (Ref: No)
Diagnosed with substance abuse
Cigarette Smoking Status (Ref: Nonsmoking)
Smoking
CD4 Cell Count
Metabolic Syndrome (Ref: 0-1 Components)
2 Components indicated
≥3 Components indicated
Note: *p < 0.05. ** p < 0.01. ***p < 0.001.

Model 2: MetSyn with
Detectable VL

Model 3: Smoking and MetSyn
with Detectable VL

B
-0.025

95% CI
(0.881, 1.080)

AOR
0.975

B
0.022

95% CI
(0.930, 1.124)

AOR
1.022

B
-0.020

95% CI
(0.885, 1.086)

AOR
0.980

0.612
0.345
-0.220

(0.696, 4.886)
(0.318, 6.268)
(0.237, 2.716)

1.844
1.411
0.803

0.633
0.581
0.004

(0.721, 4.919)
(0.409, 7.812)
(0.307, 3.280)

1.883
1.79
1.004

0.647
0.468
-0.189

(0.718, 5.084)
(0.358, 7.120)
(0.245, 2.803)

1.911
1.597
0.828

-0.092

(0.546, 1.523)

0.912

-0.080

(0.552, 1.545)

0.923

-0.090

(0.545, 1.532)

0.914

-0.522

(0.264, 1.334)

0.593

-0.613

(0.241, 1.215)

0.542

-0.507

(0.268, 1.356)

0.602

-0.066

(0.490, 1.788)

0.937

0.138

(0.614, 2.146)

1.148

-0.050

(0.496, 1.824)

0.951

0.719
-0.223

(1.101, 3.823)
(0.733, 0.872)

2.051*
0.800***

---0.226

--(0.731, 0.871)

--0.798***

0.712
-0.227

(1.090, 3.811)
(0.730, 0.870)

2.038*
0.797***

-----

-----

-----

0.365
0.554

(0.818, 2.536)
(0.996, 3.039)

1.440
1.740

0.360
0.551

(0.811, 2.532)
(0.987, 3.047)

1.433
1.734

ART antiretroviral therapy, VL viral load, MetSyn Metabolic Syndrome
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CHAPTER 4 - Focus on single tablet regimen and lipid profile
among youth living with HIV in multidisciplinary adolescent HIV
care settings
Abstract
Background: HIV itself and antiretroviral therapy (ART) are known to contribute to the
elevated risk of cardiovascular disease (CVD), including lipid abnormalities. Although early
treatment with ART might reduce the negative effect of HIV on overall cardiovascular risk,
many HIV medications have intrinsic toxicity profiles. Single tablet regimens (STRs) have
become an integral part of HIV management. STR has the potential for improved adherence due
to a lower pill burden, especially among youth living with HIV (YLH). The current study
examined whether detectable VL and STR contribute to lipid abnormalities among YLH aged
14-26y.
Methods: We analyzed a sub-sample of 398 de-identified electronic health records of YLH
extracted from multidisciplinary adolescent HIV clinics for the Adolescent Medicine Trials
Network 154 Cascade Monitoring Protocol. We conducted bivariate and multivariable logistic
regression analyses to examine differences in lipid abnormalities by VL and STR status.
Results: Our sample included a higher proportion of Black (305, 76.8%) and males (69.6%) with
mean age of 21y. Nearly half (44.4%) of YLH had a detectable VL and a majority of YLH were
currently on ART. Nearly half (40.7%) of YLH did not meet the ideal range of HDL and 28.5%
were in the clinically high range of LDL cholesterol. Similarly, 15.1% of YLH had high total
cholesterol and 15.4% had high triglycerides. Among those who were currently prescribed STR,
we observed a significantly lower proportion of YLH with high total cholesterol compared to
those who were not on STR (14.2% vs. 33.3%; p < 0.05). Among those with detectable VL, we
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observed a significantly higher proportion of YLH with low HDL compared to those without
detectable VL (50.9% vs. 33.3%; p < 0.001). After adjusting for demographic and clinical
covariates, treatment with STR was associated with significantly decreased odds of having high
total cholesterol (AOR = 0.14; 95% CI = 0.03, 0.59; p < 0.01) and low HDL (AOR = 0.17, 95%
CI = 0.03, 0.88; p < 0.05) compared to those not on STR. On the other hand, having a detectable
VL significantly increased the odds of having low HDL compared to those without detectable
VL (AOR = 2.07; 95% CI = 1.24, 3.47; p < 0.01).
Conclusions: Detectable VL was associated with significantly increased odds of having low
HDL, while the use of STR was associated with a more favorable lipid profile. Our findings
suggest the adoption of STR may be an important strategy to lower VL and protect YLH against
metabolic dysfunction associated with HIV.

Keyword(s): Single tablet regimen, lipid profile, VL, metabolic dysfunction, youth living with
HIV
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Introduction
HIV infection itself and antiretroviral therapy (ART) are both known to contribute to the
elevated risk of cardiovascular disease (CVD), including lipid abnormalities in the HIV-positive
population.1-4 Lipid abnormalities are common in patients with HIV who are receiving ART.1,5,6
Persistent inflammation and chronic immune activation contribute substantially to lipid
abnormalities, resulting in premature CVD despite viral suppression.6 Lipid abnormalities is not
an adult-only health concern, especially in the HIV-positive population. Youth living with HIV
(YLH) can be at risk of developing lipid abnormalities. However, there are currently no specific,
evidence-based recommendations for managing lipid levels in HIV-positive youth and
adolescents.
According to the National Heart, Lung, and Blood Institute (NHLBI) guidelines for youth
and young adults, screening is recommended at ages 9 to 11y and is repeated every 5 years.7
Despite the lack of specific national guidelines, because of the association of ART with lipid
abnormalities, those with HIV are recommended to undergo lipid testing routinely throughout
care,1 however, this is not currently practiced routinely in youth and the recommendation did not
specifically mention youth. The HIV Medicine Association of the Infectious Disease Society of
America and the guidelines on antiretroviral management of patients with HIV infection from
the U.S. Department of Health and Human Services recommend screening for lipid abnormalities
at baseline, prior to initiating ART, within one to three months after starting a new regimen and
every 6 to 12 months thereafter.8,9
Screening for lipid abnormalities in younger adults is an area of significant uncertainty as
there is no evidence that it leads to improved patient outcomes and there are potentially
substantial costs in routine screening the entire population.10,11 However, HIV-positive youth
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with detectable viral load (VL) and currently taking ART could benefit from routine screening
for lipid abnormalities, especially for identifying those at increased risk for CVD and receiving
interventions aimed at reducing cardiovascular risk.1 HIV itself has been shown to alter lipid
profile but the presence of traditional cardiovascular risk factors, such as hypertension and
cigarette smoking, among this patient population increases substantially the risk of CVD.2,4
While early treatment with ART might reduce the negative effect of HIV on overall
cardiovascular risk, many HIV medications have intrinsic toxicity profiles contributing to lipid
abnormalities.2,4 For the HIV-positive population, this suggests the importance of analyzing the
impact of HIV medications on lipid profiles. With the use of newer antiretroviral agents, it is also
prudent to distinguish between agents within each class to help HIV care providers make
decisions on what medications to prescribe or when to change an HIV regimen in the context of
overall health.
Single tablet regimens (STRs) are one-pill-a-day and have become an integral part of
initial ART for the management of HIV.12 A STR is a fixed-dose combination of two or more
HIV drugs from the same or different classes.12-14 The single, one-dose pill has the potential for
improved adherence due to a lower pill burden,12 especially among YLH. As such, STRs are
currently the most preferred prescription choices for HIV treatment in the US.13 The first STR
approved by the Food and Drug Administration (FDA) in 2006, Atripla, represents a viable
option whether beginning in a naïve patient or switching HIV regimens.12,14,15 Other commonly
prescribed STRs include Complera, Stribild, and Triumeq.12 Atripla and Complera consist of one
different non-nucleoside reverse transcriptase inhibitor (NNRTI) and two of the same nucleoside
reverse transcriptase inhibitor (NRTI) agents.12,14 Tenofovir and emtricitabine are the first-line
NRTIs that do not have an adverse effect on lipid profiles.2 In a trial of treatment-naïve patients
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initiating the newer formulation of tenofovir, tenofovir alafenamide vs. tenofovir disoproxil
fumarate, as one of the four agents of the STR, the ratio of total cholesterol to high-density
lipoprotein (HDL) remained unchanged for both regimens.16,17 It is not known if these findings
extend to youth.
Although NNRTIs are associated with an increase in low-density lipoprotein (LDL)
cholesterol and total cholesterol levels, this increase is counterbalanced by an increase in HDL
cholesterol during treatment with NNRTI therapy.18 Rilpivirine, which is available as a
component of Complera, appears to have favorable overall lipid profile when compared with
efavirenz, a component of Atripla.19-21 In two large trials of ART-naïve HIV-positive participants
initiating an NNRTI-based regimen, efavirenz increased total cholesterol, HDL cholesterol, LDL
cholesterol, and triglyceride levels when compared with rilpivirine.20,21 Since increases in the
HDL cholesterol fraction are considered cardioprotective and that HDL was significantly
increased among those receiving efavirenz, there was no difference in changes of the total
cholesterol/HDL cholesterol ratio between the two treatments.2,20,21
Elsewhere, prior studies show an association between protease inhibitors (PIs) and
cardiovascular events.22-24 The recommended PIs that require a low dose of ritonavir for boosting
darunavir have been associated with lipid abnormalities.25 All agents in the integrase inhibitor
(II) class are associated with favorable lipid profiles.2 Overall, most of the agents available as a
component of STR have been shown to have a favorable lipid profile, at least in adult patients.
The current study was undertaken to examine the associations of VL status and STR treatment
with lipid profiles among YLH.

Methods
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Study Design and Population
The data for this paper were drawn from one of the protocols of the Adolescent Medicine
Trials Network (ATN) Scale It Up initiative, the ATN Cascade Monitoring Study.26 Deidentified electronic health records (EHR) were requested from ten participating sites for the
baseline year between January 1, 2016 and December 31, 2016 as described previously.27 To be
included in these analyses, data on a patient’s age, race, ethnicity, gender, height, weight, CD4
cell count results, VL results, systolic blood pressure, cholesterol panel, blood pressure
medications, ART medications, and the International Statistical Classification of Disease and
Related Health Problems Tenth Revision (ICD-10) diagnosis codes for cigarette smoking,
alcohol and drugs were required. Because Brooklyn, Miami, Philadelphia, and San Diego did not
provide gender, systolic blood pressure, and cholesterol data, these 4 sites were excluded from
further analyses (see Table 1). The Institutional Review Boards of both Florida State University
and the City University of New York approved to conduct analyses of de-identified data.
Measures
Demographics. We defined age as a continuous variable in years as reported by site.
Gender, race, and ethnicity definitions varied within a site’s data. These demographic variables
were constructed as reported by site. For gender we constructed a binary variable of male vs.
female. Race/ethnicity variable was categorized into Black, Latino, White, Hispanic, or Other.
Missing race for one patient was kept as missing data and removed from these analyses.
HIV and immunologic biomarkers. Earliest date reported VL values in “copies/mL” by
site were used. VL threshold detectability was coded as binary. Missing VL results for four
patients were not included in these analyses. Based on the guidelines for the Use of
Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, we defined
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immunocompromised as CD4 T lymphocyte cell count of less than or equal to 200.28,29 We
created a binary variable of CD4 cell count with “baseline count ≤ 200” and “baseline count
>200.” Missing CD4 results for 13.8% (n = 55) of the sample were not included in these
analyses.
ART medication. All prescribed HIV medications were coded into a dichotomous
variable. Missing values were assumed to be the result of no prescription by doctors and were
recoded into the category of non-ART medication.
Substance abuse diagnosis: We used ICD-10 codes F1010, F1210, F1220, F1290, F1510,
F1511, F1520, F1590, F17200, F17210, F1910, and F1920 to identify alcohol and drugs such as
amphetamines, cannabis, cocaine, hallucinogens, and opioids. A dichotomous variable was
created for patients having any vs. no substance abuse. Missing values were coded as no
substance abuse.
Body mass index (BMI). BMI, a measure of weight relative to height (kg/m2) was used to
serve as a proxy of adiposity. Tallest and earliest reported value for height and highest and
earliest reported value for weight were used. Patients (n = 7) with missing values were removed
from further analyses.
Systolic blood pressure. Since our target population was YLH, only systolic blood
pressure as reported by site was used to construct a numeric variable.
Cigarette smoking. We used ICD-10 codes F17200 and F17210 for tobacco use. If these
codes were missing, we pulled data from patient self-report such as current status and never
smoked at each site. A dichotomous variable for smoking was created.
Triglycerides and HDL cholesterol. We defined hypertriglyceridemia as the fasting
triglyceride levels ≥ 150 mg/dL.30 For low HDL cholesterol, < 45 mg/dL was used for males and
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females aged 19y or younger,7 while ≤ 40 mg/dL and < 50 mg/dL were used for men and women
aged 20y or older, respectively.7
Total cholesterol and LDL cholesterol. For high total cholesterol, ≥ 170 mg/dL was used
for males and females aged 19y or younger, while > 200 mg/dL was used for men and women
aged 20y or older, respectively.7 We defined high LDL cholesterol as the fasting blood LDL
levels ≥ 100 mg/dL.7
ART prescribed categories. The extracted medication files received from the sites were
initially coded into five types of ART. Combinations of three or more HIV medicines from at
least two different HIV drug classes were coded as STR as displayed in Table 2. The remaining
HIV medicines were coded as NRTI, NNRTI, PI, and II. The earliest visit date with the first
ART prescribed status was used to categorize HIV treatment regimen for the baseline medication
data. We then created a patient-level dataset with a dichotomous indicator for every medication
code. A count variable was also created for the number of different drug classes prescribed per
patient.
Data Analysis
For this study, we focused on a subset of patients (n = 398) from the baseline analytic
sample of 813 health records collected in 2016 in order to incorporate HIV treatment regimen
and lipid profile. First, we performed a descriptive analysis of demographic and clinical
characteristics of the sample documented in the EHR system across the U.S. Second, we created
a dichotomous indicator for each lipid and conducted bivariate analyses using all four lipid
indicators individually as an outcome as opposed to using a categorial variable of lipid profile
with four groups. We analyzed our results across lipid outcomes by STR and VL status in the
bivariate analyses. Chi-square tests of independence were used for categorical variables and
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independent samples t-tests were performed for continuous variables. Third, we ran a series of
three multivariable logistic regression models with total cholesterol as a dichotomous outcome
variable. The first model was constructed to determine whether HIV-positive youth with
detectable VL are more likely to have high total cholesterol as compared to those with
undetectable VL. The second model was constructed to examine whether STR was
independently associated with total cholesterol level in YLH. The third model was constructed to
examine the combined effect of detectable VL and STR with total cholesterol level. Covariates
included demographic variables (age, race/ethnicity, and gender) and BMI, systolic blood
pressure, substance dependence, cigarette smoking, and CD4 cell count. Adjusted odds ratios
(AOR) from the models are presented for the odds of classfication with high total cholesterol
relative to normal total cholesterol as the reference group.
Finally, we repeated the series of three multivariable logistic regression models with low
HDL cholesterol as the outcome variable and the same independent variables and covariates. For
our lipid models, we performed multivariable analyses for the total cholesterol and HDL only
since these are the two predicting factors included in the Framingham Risk Score and the other
two lipids were not observed to be statistically significant in the bivariate comparisons. All
analyses were performed in IBM SPSS Statistics 25 and syntax files were developed to construct
new variables and recode some variables based on the analytic design. The threshold for
statistical significance was 0.05.

Results
Demographic and clinical characteristics of the analytic sample (n = 398) are displayed in
Table 3. The mean age was 21y with a range of 14 to 26 years (SD = 2.7). The majority of the
patients identified as Black (76.8%) followed by Other (10.6%), White (6.8%), and Latino
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(5.8%). More than half (69.6%) of the sample were male. The mean VL, a measure of ART
adherence was 22440 (SD = 93965.4). Nearly half (44.4%) had a detectable VL. Among those
with a detectable VL, 29.9% had > 1000 copies/mL. The mean CD4 cell count was 633 (SD =
302.3). Among those with a CD4 cell count value available, 7.3% had a baseline count of ≤ 200
indicating immunocompromised status.
Among those sites with the required data for this study, Memphis had the largest sample
size (n = 157; 39.4%). The mean BMI was 25 kg/m2 with a range of 4.8 to 69.5 (SD = 6.7) and
the mean systolic blood pressure was 129 mmHg with a range of 92 to 180 (SD = 11.7). Of the
398 YLH, 15.6% were diagnosed with substance abuse and 26.9% had ICD-10 codes for tobacco
use. Of those with cholesterol data, 15.1% had high total cholesterol; 28.1% had high LDL
cholesterol; 15.4% had hypertriglyceridemia; and 40.7% had low HDL cholesterol level. The
majority of patients 92.2% (n = 367) were currently taking ART. Of the active ART users, 95.9%
were prescribed STR on the earliest visit date.
Bivariate correlates across lipid outcomes
STR vs. non-STR groups. Examining the cholesterol outcomes in STR vs. non-STR
groups, several general trends emerged that are displayed in Table 4. First, we performed chisquare tests to compare the differences across total cholesterol outcomes by STR group. Among
those who were currently prescribed STR compared to those not on STR, we observed a
significantly lower proportion of patients with high total cholesterol (14.2% vs. 33.3%; p < 0.05).
Second, we performed the chi-square tests to compare the differences across high LDL
cholesterol outcomes by STR group. Among those who were currently prescribed STR compared
to those not on STR, no significant differences (p > 0.05) were observed with high LDL
cholesterol. Third, we performed the chi-square tests to compare the differences across HDL
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cholesterol outcomes by STR group. Among those who were currently prescribed STR compared
to those not on STR, no significant differences (p > 0.05) were observed with low HDL
cholesterol. Fourth, we performed the chi-square tests to compare the differences across
hypertriglyceridemia outcomes by STR group. Among those who were currently prescribed STR
compared to those not on STR, no significant differences (p > 0.05) were observed with
hypertriglyceridemia.
Detectable vs. undetectable VL. Examining the cholesterol outcomes by VL status, we
observed a significant difference only across HDL cholesterol outcomes as displayed in Table 4.
Among those who had detectable VL compared to those who had undetectable VL, we observed
a significantly higher proportion of patients with low HDL cholesterol (50.9% vs. 33.3%; p <
0.001). However, no significant differences (p > 0.05) were observed in other cholesterol
outcomes when comparing patients who had detectable VL with those who had undetectable VL.
Refer to Table 4 for demographic and other ART differences across cholesterol outcomes.
Multivariable analyses across total cholesterol and HDL cholesterol outcomes
STR vs. non-STR groups. Multivariable logistic regression across total cholesterol and
HDL outcomes by STR group are displayed in Table 5 and Table 6. Model 1A presents the
association of STR alone with high total cholesterol. After adjusting for demographic and
clinical differences, treatment with STR significantly decreased the odds of the patient having
high total cholesterol compared to those not on STR (AOR = 0.16; 95% CI = 0.04; 0.65; p <
0.05). Model 2A presents the association of STR alone with low HDL cholesterol. After
adjusting for demographic and clinical differences, treatment with STR significantly decreased
the odds of the patient having low HDL cholesterol compared to those not on STR (AOR = 0.16;
95% CI = 0.03, 0.83; p < 0.05).
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Detectable vs. undetectable VL. Multivariable logistic regression across total cholesterol
and HDL outcomes by VL status are displayed in Table 5 and Table 6. Model 1B presents the
association of detectable VL alone with high total cholesterol. After adjusting for demographic
and clinical differences, having a detectable VL did not significantly increased the odds of the
patient having high total cholesterol compared to those without detectable VL (p > 0.05). Model
2B presents the association of detectable VL alone with low HDL cholesterol. After adjusting for
demographic and clinical differences, having a detectable VL significantly increased the odds of
the patient having low HDL cholesterol compared to those without detectable VL (AOR = 1.97;
95% CI = 1.21, 3.21; p < 0.01).
STR and detectable VL. Multivariable logistic regression across total cholesterol and
HDL outcomes by STR and detectable VL together are displayed in Table 5 and Table 6. Model
1C presents the association of STR and detectable VL together with high total cholesterol. After
adjusting for demographic and clinical differences, treatment with STR significantly decreased
the odds of the patient having high total cholesterol compared to those not on STR (AOR = 0.14;
95% CI = 0.03, 0.59; p < 0.01) whereas detectable VL was not found to be independently
associated with high total cholesterol. Model 2C presents the association of STR and detectable
VL together with low HDL cholesterol. After adjusting for demographic and clinical differences,
treatment with STR significantly decreased the odds of the patient having low HDL cholesterol
compared to those not on STR (AOR = 0.17; 95% CI = 0.03, 0.88; p < 0.05). Similarly, having a
detectable VL significantly increased the odds of the patient having low HDL cholesterol
compared to those without detectable VL (AOR = 2.07; 95% CI = 1.24, 3.47; p < 0.01). Refer to
Table 5 and Table 6 for age, gender, systolic BP, and CD4 differences across cholesterol
outcomes.
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Discussion
The purpose of this study was to examine whether STR regimen and detectable VL were
associated with lipid outcomes in U.S.-based YLH aged 14-26y treated at multidisciplinary
adolescent HIV care settings. Our study is the first to report estimated prevalence of lipid
abnormalities in YLH and had a relatively healthy sample who were predominantly on STR. We
found that nearly half (40.7%) of YLH did not meet the ideal range of HDL cholesterol and
28.5% were in the clinically high range of LDL cholesterol. Similarly, 15.1% of the sample had
high total cholesterol and 15.4% had high triglycerides. These results are consistent with findings
in the National Health and Nutrition Examination Surveys (NHANES) study which analyzed
nationally representative data from more than 26,000 children and adolescents and observed
trends for levels of triglycerides and LDL cholesterol from 1999 to 2016, but only 47% to 50%
of U.S. youth had all lipids at ideal levels and 19% to 25% had at least one adverse level.31 The
NHANES study analyzed U.S. population-weighted data for youth aged 6 to 19 years and did not
include HIV status. This study helps to fill this gap and shows that EHR data could be leveraged
more routinely to examine CVD risk factors in special populations such as YLH.
Our findings supporting the hypothesis that patients on STR have a higher likelihood of
not experiencing lipid dysfunction is consistent with previous studies targeting adults.2,16,17,19-21
However, with the newer formulation of STR, EHR data can be used to conduct longitudinal
studies and distinguish between agents within each single tablet regimen and their impact on
lipid profiles. These data can be efficiently collected and analyzed to generate prediction models
to identify HIV-positive youth at risk for CVD due to lipid abnormalities. With the use of
longitudinal data, future research can estimate the differences in lipid levels at multiple time
points and examine percent change from baseline to promote STRs with the most favorable lipid

90

profile for YLH. In particular, because the use of some protease inhibitors have been associated
with changes in lipid levels and are included as a component of STR,2 lipids should be evaluated
before and subsequent to protease inhibitor initiation.
Our findings also support the hypothesis that patients with detectable VL are more likely
to have low HDL cholesterol. The mechanism for these observations is unclear but it is likely to
be related to impaired cholesterol synthesis. Recent studies have focused on measuring plasma
HDL functionality using a cholesterol efflux (CE) capacity assay, an emerging cell-based assay
that predicts CVD events in the general population and could be used as a biomarker of
atherosclerosis.32,33 In the field of HIV, one postulated mechanism links HIV inhibition of
cholesterol efflux from accumulation of lipids within macrophages.2 A recent study observed
patients with detectable VL revealed impaired CE capacity compared with healthy individuals
and that immune status secondary to HIV progression and exposure influence plasma HDL-CE
capacity.33
The present study showing VL non-suppression linked with lipid abnormalities is new
and has two important clinical implications for YLH. The last decade has seen a burgeoning
evidence indicating that HIV infection itself is a risk factor for coronary heart disease and that
HIV itself has been shown to increase lipogenesis in the liver and to alter the lipid profile.2 Our
finding suggests VL monitoring is critical to ensure VL suppression in YLH because suppression
of HIV itself may be cardioprotective, possibly by reducing proinflammatory cytokines (e.g.,
interleukin-6) that play a role in arterial inflammation.34,35 However, performing traditional
serological testing requires youth to schedule an appointment either with their primary care
provider or a laboratory to extract the serum from blood specimens. Utilizing technology and
promoting self-management (e.g., using home-based dried blood spot as a VL monitoring
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device) may be beneficial but requires more implementation science research. In addition, our
finding also suggests screening earlier for lipid abnormalities and follow-up lipid screening,
especially for HIV-positive youth at higher cardiovascular risk (hypertension, diabetes, cigarette
smoking). Screening earlier may be appropriate for patients and their primary care physicians to
discuss lifestyle changes (e.g., diet modification, exercise regimen) and manage cholesterol
levels. If lifestyle changes are unachievable or ineffective, earlier screening will help health care
providers assess patients’ willingness to initiate treatment with cholesterol medications (e.g.,
statins). Strategies to promote adherence to such medications among YLH warrants further
research.
Screening for the full lipid profile is performed in the U.S. to measure the total
cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides in the blood.10,36 The total
cholesterol and HDL are the only two lipids required for predicting cardiovascular risk,10
although use of Framingham Risk Score is not validated in patients with HIV.37 Some studies
found that the Framingham multivariable risk algorithm underestimated the presence of
subclinical atherosclerosis (i.e. the buildup of plaque in the blood vessels) in patients with HIV,
over-predicted rates in patients who did not receive ART, and under-predicated rates in patients
on ART. 37,38 These findings highlight the need to incorporate ART into cardiovascular risk
equations in HIV-positive populations.
This study has some limitations. The study design was cross-sectional so no causality
could be inferred. Because cholesterol data were not provided by four sites, our analytical sample
was limited to predominately Black YLH, impacting the generalizability of our results. Since the
code was originally written for baseline dataset, we used earliest visit data for coding HIV
medications, which may lead to misclassification of drugs. Future studies should seek to
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combine all medical visits to more accurately assess the scope of medication use and any
differences between medical visits. This would be beneficial for evaluating trends in STRs
prescribed and duration of STRs used among YLH. With the U.S. pharmaceutical drug net
spending USD 324 billion in 2017,39 our findings can be used to examine trends in prices among
most commonly prescribed STRs to address concerns related to costs and health policy in the
U.S. Individual ART agents might differ in their contributions to the risk of lipid abnormalities.
Therefore, instead of examining a class effect, understanding which type of ART contributes to
the increased risk of lipid abnormalities would be incredibly valuable. Finally, although
regression was used for adjusting confounders, residual confounders cannot be avoided and it
can bias the association in any direction (towards or away from the null). Despite these
limitations, our findings show that it is feasible to leverage EHRs to examine chronic disease
risks in YLH and highlight the need to monitor HIV treatment in the context of overall health
even in a young HIV-positive population.
The present study indicates that VL non-suppression is positively and independently
associated with lipid abnormalities in YLH, while STR was observed to be protective against
lipid abnormalities, and these observations supplement the existing knowledge on the
relationship among VL, STR, and lipid outcomes. In HIV-positive individuals, both the infection
itself and its treatment with ART may contribute to an increased risk of CVD by altering blood
lipid levels, inducing inflammation, and impacting blood-clotting processes, all of which can
enhance CVD risk. With more effective and widespread use of STR among YLH, the impact of
ART agents on lipid profiles must be analyzed carefully and it is important to implement more
integrated care for this population. Because there is such a lack of knowledge on CVD, HIV, and
youth’s intersection, prevention is critical in these populations.
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Table 1. Data Sources
City
Baltimore
Birmingham
Los Angeles
Memphis
Tampa
Washington DC
Total

n
%
72 18.1
44 11.1
67 16.8
157 39.4
54 13.6
4
1.0
398 100.0
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Table 2. Components of Single Tablet Regimen
Brand
Name
Atripla

Complera

Delstrigo

Genvoya

Odefsey

Stribild

Symtuza

Triumeq

Components
600 mg efavirenz
200 mg emtricitabine
300 mg tenofovir disoproxil fumarate
25 mg rilpivirine
200 mg emtricitabine
300 mg tenofovir disoproxil fumarate
100 mg doravirine
300 mg lamivudine
300 mg tenofovir disoproxil fumarate
150 mg elvitegravir
150 mg cobicistat
200 mg emtricitabine
10 mg tenofovir alafenamide
25 mg rilpivirine
200 mg emtricitabine
25 mg tenofovir alafenadmide
50 mg elvitegravir
150 mg cobicistat
200 mg emtricitabine
300 mg tenofovir disoproxil fumarate
800 mg darunavir
150 mg cobicistat
200 mg emtricitabine
10 mg tenofovir alafenamide
50 mg dolutegravir
600 mg abacavir
300 mg lamivudine

HIV Drug Category
Non-nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Non-nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Non-nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Integrase inhibitor
CYP3A inhibitor
Nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Non-nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Integrase inhibitor
CYP3A inhibitor
Nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Protease inhibitor
CYP3A inhibitor
Nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor
Integrase inhibitor
Nucleoside reverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitor

Sources: AIDSinfo last reviewed June 24, 2019 FDA-approved medicines fact sheet; Truong et al. (2015) Oncedaily, single-tablet regimens for the treatment of HIV-1 infection
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Table 3. Demographic and Clinical Characteristics of the Sample (N = 398)
Race/Ethnicity (n = 397)
Black
Latino
White
Other
Gender
Male
Female
Viral Load (n = 394)
Detectable VL
Undetectable VL
CD4 Cell Count (n = 343)
Baseline count ≤ 200
Baseline count > 200
Substance Abuse Diagnosis
Diagnosed with substance abuse
Not diagnosed with substance abuse
Cigarette Smoking
Current smoking
Non-smoking
ART Status
Currently on ART
Not reportedly on ART
ART Prescribed Categories (n = 367)
NRTI
NNRTI
PI
STR
II
Type of ART Prescribed
One
Two
Three
Four
Lipid Profile
High Total Cholesterol
High LDL Cholesterol (n = 397)
Hypertriglyceridemia (n = 395)
Low HDL Cholesterol
Age (Range: 14 - 26; Mdn. = 21)
BMI (Range: 4.8 - 69.5; Mdn. = 23.5)
Systolic BP (Range: 92 - 180; Mdn. = 130)

n

%

305
23
27
42

76.8
5.8
6.8
10.6

277
121

69.6
30.4

175
219

44.4
55.6

25
318

7.3
92.7

62
336

15.6
84.4

107
291

26.9
73.1

367
31

92.2
7.8

13
8
64
352
81

3.5
2.2
17.4
95.9
22.1

246
95
22
4

67.0
25.9
6
1.1

60
113
61
162
M
21
26
129

15.1
28.5
15.4
40.7
SD
2.7
7.1
11.7

ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor; STR, single tablet regimen; II, integrase inhibitor

LDL, low-density lipoproteins; HDL, high-density lipoproteins; BMI, body mass index; BP, blood pressure

98

Table 4. Bivariate Analysis by Lipid Profile

Race/Ethnicity
Black
Latino
White
Other
Gender
Male
Female
Viral Load
Detectable VL
Undetectable VL
CD4 Cell Count
Baseline count ≤ 200
Baseline count > 200
Substance Abuse Diagnosis
Diagnosed
Not diagnosed
Cigarette Smoking
Current smoking
Non-smoking
ART Status
Currently on ART
Not reportedly on ART
ART Prescribed Categories
NRTI
NNRTI
PI
STR
II

High Total Cholesterol
n = 60
Test Statistics
n
%
df
χ²

High LDL Cholesterol
n = 113
Test Statistics
n
%
df
χ²

Low HDL Cholesterol
n = 162
Test Statistics
n
%
df
χ²

Hypertriglyceridemia
n = 61
Test Statistics
n
%
df
χ²

43
4
6
6

72.9
6.8
10.2
10.2

3

1.424

84
8
10
10

75.0
7.1
8.9
8.9

3

1.977

127
7
12
16

78.4
4.3
7.4
9.9

3

1.388

34
6
10
11

55.7
9.8
16.4
18.0

3

19.488***

43
17

71.7
28.3

1

0.143

81
32

71.7
28.3

1

0.348

95
67

58.6
41.4

1

15.499***

53
8

86.9
13.1

1

10.419***

23
36

39.0
61.0

1

0.830

49
63

43.8
56.3

1

0.039

89
73

54.9
45.1

1

12.338***

24
37

39.3
60.7

1

0.704

5
44

10.2
89.8

1

0.719

8
88

8.3
91.7

1

0.215

17
120

12.4
87.6

1

8.850**

6
47

11.3
88.7

1

2.066

6
54

10.0
90.0

1

1.671

17
96

15.0
85.0

1

0.039

25
137

15.4
84.6

1

0.004

8
53

13.1
86.9

1

0.363

16
44

26.7
73.3

1

0.002

36
77

31.9
68.1

1

2.147

46
116

28.4
71.6

1

0.317

19
42

31.1
68.9

1

0.602

55
5

91.7
8.3

1

0.029

100
13

88.5
11.5

1

2.997

152
10

93.8
6.2

1

0.993

56
5

91.8
8.2

1

0.012

3
3
18
50
16

5.5
5.5
32.7
90.9
29.1

1
1
1
1
1

0.692
3.254
10.503***
4.132*
1.854

2
3
23
94
26

2.0
3.0
23.0
94.0
26.0

1
1
1
1
1

0.967
0.427
3.233
1.266
1.195

3
3
30
143
43

2.0
2.0
19.7
94.1
28.3

1
1
1
1
1

1.868
0.052
0.952
2.226
5.834*

2
2
14
52
13

3.6
3.6
25.0
92.9
23.2

1
1
1
1
1

0.000
0.581
2.513
1.530
0.035
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M
SD
df
F
M
SD
df
F
M
SD
df
F
M
SD
df
F
Age
20
2.9
396
2.138**
21
2.7
395
1.139
21
2.8
396
1.376
21
2.8
393
0.675
BMI
26
7.9
396
0.058
27
7.4
395 0.497*
27
7.9
396 19.277***
28
6.7
393
0.448*
Systolic BP
130 11.4 396
0.096
130 11.5 395
0.120
130 11.6 396
0.129
130 10.6 393
1.518
Note: *p < 0.05. ** p < 0.01. ***p < 0.001.
ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; STR, single tablet
regimen; II, integrase inhibitor
LDL, low-density lipoproteins; HDL, high-density lipoproteins; BMI, body mass index; BP, blood pressure

Table 5. Multivariable Logistic Regression by High Total Cholesterol†

Age
Race/Ethnicity (Ref: White)
Black
Latino
Other
Male (Ref: Female)
BMI
Systolic BP
Detectable VL (Ref: Undetectable VL)
CD4 Cell Count ≤ 200 (Ref: CD4 cell count > 200)
Diagnosed with Substance Abuse (Ref: Not diagnosed)
Current Cigarette Smoking (Ref: Non-smoking)

Model 1A: High Total
Cholesterol with STR
B
95% CI
AOR
-0.19
(0.71, 0.96)
0.824*

Model 1B: High Total Cholesterol
with VL
B
95% CI
AOR
-0.21
(0.71, 0.94)
0.815**

Model 1C: High Total Cholesterol
with STR and VL
B
95% CI
AOR
-0.23
(0.68, 0.93)
0.794**

-0.60
-0.99
-0.02
-0.12
0.02
0.02
--0.27
-0.26
0.28
-1.83

-0.53
-1.05
-0.35
0.12
0.02
0.01
-0.44
0.53
-0.24
0.40
---

-0.57
-0.93
-0.04
0.021
0.02
0.02
-0.50
0.51
-0.25
0.44
-1.98

(0.16, 1.86)
(0.03, 4.23)
(0.22, 4.33)
(0.38, 2.08)
(0.97, 1.07)
(0.98, 1.05)
--(0.40, 4.30)
(0.23, 2.15)
(0.51, 3.42)
(0.04, 0.65)

STR Prescribed (Ref: STR not prescribed)
Note: *p < 0.05. ** p < 0.01. ***p < 0.001.
†Dependent variable reference group: Normal Total Cholesterol
BMI, body mass index; BP, blood pressure; STR, single tablet regimen

0.55
0.37
0.98
0.89
1.02
1.02
--1.31
0.77
1.33
0.16*

(0.19, 1.76)
(0.03, 3.59)
(0.18, 2.84)
(0.50, 2.52)
((0.97, 1.07)
(0.98, 1.04)
(0.33, 1.28)
(0.51, 5.65)
(0.29, 2.11)
(0.62, 3.61)
---

0.59
0.35
0.71
1.13
1.02
1.01
0.65
1.70
0.79
1.49
---

(0.16, 1.95)
(0.03, 4.51)
(0.21, 4.35)
(0.43, 2.45)
(0.97, 1.08)
(0.99, 1.06)
(0.29, 1.27)
(0.48, 5.78)
(0.27, 2.23)
(0.58, 4.13)
(0.03, 0.59)

0.56
0.40
0.97
1.02
1.02
1.02
0.61
1.67
0.78
1.55
0.14**
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Table 6. Multivariable Logistic Regression by Low HDL Cholesterol†

Age
Race/Ethnicity (Ref: White)
Black
Latino
Other
Male (Ref: Female)
BMI
Systolic BP
Detectable VL (Ref: Undetectable VL)
CD4 Cell Count ≤ 200 (Ref: CD4 cell count > 200)
Diagnosed with Substance Abuse (Ref: Not diagnosed)
Current Cigarette Smoking (Ref: Non-smoking)

Model 2A: Low HDL Cholesterol
with STR
B
95% CI
AOR
(0.88, 1.08)
-0.03
0.97
-0.42
-1.22
-0.14
-1.23
0.02
0.03
--1.48
0.08
0.12
-1.84

(0.25, 1.77)
(0.05, 1.59)
(0.26, 2.95)
(0.16, 0.54)
(0.98, 1.05)
(1.01, 1.06)
--(1.59, 12.06)
(0.54, 2.18)
(0.57, 2.20)
(0.03, 0.83)

0.66
0.30
0.87
0.29***
1.02
1.03*
4.39**
1.08
1.12
0.16*

Model 2B: Low HDL Cholesterol
with VL
B
95% CI
AOR
-0.01 (0.89, 1.10)
1.00
-0.59
-1.59
-0.32
-1.21
0.03
0.03
0.68
1.21
0.09
0.01
---

STR Prescribed (Ref: STR not prescribed)
Note: *p < 0.05. ** p < 0.01. ***p < 0.001.
†Dependent variable reference group: Normal HDL Cholesterol
BMI, body mass index; BP, blood pressure; STR, single tablet regimen; HDL, high-density lipoproteins

(0.22, 1.37)
(0.04, 1.05)
(0.23, 2.27)
(0.16, 0.54)
(0.99, 1.07)
(1.00, 1.05)
(1.21, 3.21)
(1.27, 8.77)
(0.56, 2.13)
(0.53, 1.89)
---

0.55
0.20
0.73
0.30***
1.03
1.03*
1.97**
3.34*
1.09
1.01
---

Model 2C: Low HDL Cholesterol
with STR and VL
B
95% CI
AOR
-0.02

(0.89, 1.09)

0.99

-0.45
-1.27
-0.08
-1.23
0.02
0.03
0.73
1.20
0.11
-0.05
-1.79

(0.24, 1.69)
(0.05, 1.57)
(0.27, 3.14)
(0.15, 0.53)
(0.98, 1.06)
(1.00, 1.05)
(1.24, 3.47)
(1.19, 9.35)
(0.55, 2.23)
(0.48, 1.92)
(0.03, 0.88)

0.64
0.28
0.93
0.28***
1.02
1.03*
2.07**
3.33*
1.12
0.95
0.17*
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CHAPTER 5 – CONCLUSION
The three studies included in this dissertation were designed to examine the association
of HIV biomarkers with cardiovascular risk (Chapter 2: AIM 1), prevalence of cigarette smoking
and metabolic syndrome and their role in viral load (VL) non-suppression (Chapter 3: AIM 2),
and the association between single tablet regimen (STR) and lipid abnormalities (Chapter 4:
AIM 3) among youth living with HIV (YLH). Using de-identified electronic health records
(EHR) data extraction of YLH aged 14-26 receiving HIV medical care at 10 clinics participating
in the United States (U.S.) National Institutes of Health (NIH)-sponsored Adolescent Medicine
Trials Network for HIV/AIDS Interventions (ATN) Program – Scale It Up,1 we were able to
analyze the 2016 baseline data. Scale It Up is a network of research teams who are developing,
testing, and brining to practice self-management interventions that positively impact the youth
HIV prevention and care cascades. The ATN 154 Cascade Monitoring2 protocol team receives
extracted EHR data files annually for 5 years from the 10 clinical care sites. These sites include
Baltimore, Birmingham, Brooklyn, Los Angeles, Memphis, Miami, Philadelphia, San Diego,
Tampa, and Washington DC.
We merged specific variables of interest from the baseline data files into a single
analytic dataset of 1093 sample size for this dissertation. Because Brooklyn, Miami, and
Philadelphia did not provide gender and systolic blood pressure data, these three sites were
excluded from our analyses. Out of full sample, we developed two analytic samples based on
Cardiac Risk Score1 (n =813) and Cardiac Risk Score2 (n = 398) to address AIM 1. We used the
second analytic sample size of 398 to address AIM 2 and AIM 3. We used descriptive statistics,
chi-square, ANOVA and independent t tests, and a series of multivariable linear regression
models to examine the association of detectable VL and CD4 cell count ≤ 200 with
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cardiovascular risk among YLH. We then examined the association of cigarette smoking and
metabolic syndrome with VL by performing descriptive statistics, chi-square, ANOVA and
independent t tests, and a series of multivariable logistic regression models. Finally, we
examined the association of detectable VL and STR with lipid abnormalities by performing
descriptive statistics, chi-square, ANOVA and independent t tests, and a series of multivariable
logistic regression models. There were several important findings in this dissertation. This final
chapter will summarize key findings from these three studies, discuss clinical and public health
implications, and provide recommendations for future direction.

Key Findings and Implications
Overall, the findings from this dissertation demonstrates an emerging theme that a
relationship exists between detectable VL and increased risk of cardiovascular disease (CVD);
and it appears that smoking is associated with VL non-suppression, which then is associated with
an increased odds of having lipid abnormalities whereas STR is protective against lipid
abnormalities in YLH in the U.S. The sample was predominantly Black and male with a little
more than half (52.2%) having an undetectable VL. Despite using the clinic-based sample, the
estimated proportion achieving viral suppression is low. More work is needed to reach the Joint
United Nations Program on 90-90-90 HIV treatment targets by 2020.3 The use of traditional
treatment methods for engagement and retention to care may not be well-suited for YLH.
Chapter 2
In Chapter 2, we examined the association of detectable VL and low CD4 cell count with
cardiovascular risk in YLH. Our findings support the hypothesis that YLH with detectable VL
are at increased risk of CVD compared to those with undetectable VL as measured by cardiac
risk scores. After adjusting for demographic and clinical covariates, we found that for a 1-unit
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increase in VL, there is a 0.038 increase in log-likelihood of having CVD risk as measured by
Cardiac Risk Score2. Upon combining VL and CD4 results together plus demographic and
clinical covariates, we found significant positive association between VL and CVD risk as
measured by Cardiac Risk Score2. We observed similar findings between VL and CVD risk as
measured by Cardiac Risk Score1. However, CD4 cell count was not found to be significantly
associated with increased risk of CVD. The findings demonstrate the independent contribution of
detectable VL on CVD and highlight the importance of VL monitoring and promoting selfmanagement. Youth are less adherent to their HIV medication, less likely to see health care
providers or maintain medical appointment, less adherent to lifestyle changes. Any youth
oriented tool which could be utilized by youth to communicate risk to self and health care
provider would improve awareness and has the potential to maintain viral suppression.
Although a number of multivariate risk models and calculators have been developed over
the years, health care providers do not routinely use these tools as part of the standard CVD risk
assessment unless patients have a strong family history of premature CVD in multiple relatives.4
The Framingham general CVD risk score (2008) was shown to have reliable predictive ability4-6
and has been commonly applied in clinical practice. This approach, however, does not consider
lifetime risk and current guidelines recommend CVD risk assessment based on patient-specific
characteristics (e.g., age, gender, ethnicity).4 As such, we adapted the Framingham model to
develop two types of Cardiac Risk Scores and all patients with enough data to calculate risk were
assumed to be 21. With the elimination of age as a limiting factor from the algorithm and
development of Cardiac Risk Score1 (defined as the risk score for patients with systolic blood
pressure, smoking, diabetes, and anti-hypertensive medication use) and Cardiac Risk Score2
(defined as the risk score for patients with systolic blood pressure, smoking, diabetes, anti-
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hypertensive medication use, total cholesterol, and HDL), this study may lead to implementation
of clinical guidelines for CVD risk assessment, especially in adolescents and young adults with
HIV.
There is clearly a need for accurate CVD risk assessment in this important sub-group as
all of the risk models are highly driven by age and none of the currently available CVD risk
scores account for an individual’s HIV status, which can significantly impact the accuracy of
estimated CVD risk for YLH. In addition, we constructed a continuous variable as opposed to
using a categorical score to calculate overall risk and looked at many different risk factors of
CVD to avoid limiting to only those with overall higher risk and underestimate CVD risk for
YLH. Prior to now, the ability of the currently available methods for risk estimation in this age
range was unknown. Our results are among the first to examine these methods in estimating risk
in adolescents and young adults with HIV.
Chapter 3
In Chapter 3, we examined the association of cigarette smoking and metabolic syndrome
with VL in YLH. Our findings support the hypothesis that those who are smokers are more likely
to have high plasma VL and that the presence of the components of metabolic syndrome was not
found to be associated with the increased risk of VL non-suppression. We found that being a
smoker significantly increased the odds of having VL non-suppression even after adjusting for
demographic and clinical covariates and including metabolic syndrome in the model. On the
other hand, no statistically significant differences were found when examining the association
between ≥ 3 components of metabolic syndrome and odds of having VL non-suppression
adjusting for demographic and clinical covariates, and as such, we could not reject the null
hypothesis. Our study had a lower prevalence of cigarette smoking than previously reported two
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ATN cohort studies among YLH (32.9-38.7%).7 Prevalence estimates for the metabolic
syndrome may vary based on the criteria used; nevertheless, our study found a higher prevalence
of metabolic syndrome compared to a more recent study of 80 HIV-positive adolescents (aged
14.6-18y, 10%).8
Prior research focused on metabolic syndrome as an outcome variable and cigarette
smoking as an independent exposure variable. However, there is mixed findings about metabolic
syndrome and their potential association with cigarette smoking.9-11 One study used ATN data to
look at the effect of tobacco smoking on metabolic syndrome but the findings were not
significant.7 We wanted to test the hypothesis on a combined relationship of smoking and
metabolic syndrome since our target population is youth with HIV. For example, a young patient
with HIV and having a diagnosis of metabolic syndrome (e.g., with high blood sugar, high blood
pressure, unhealthy cholesterol levels, taking medications for all of these three conditions) and
tobacco use may be at a greater risk to have detectable VL. Our findings supplement the existing
knowledge on the relationship among smoking, metabolic syndrome, and VL.
Existing data suggest that increased cardiovascular risk in HIV-positive patients may be
associated with abnormal fat redistribution with lipoatrophy known as lipodystrophy syndrome,
and may not have overt obesity but it is often significantly associated with metabolic
syndrome.12 When a study compared the CVD risk estimates in 91 HIV-positive and HIVnegative patients from the Framingham Offspring Study who were matched for age, gender, and
body mass index (BMI), the risk estimates were significantly higher in HIV-positive patients
with evidence of fat redistribution.13 Consistent with our first study, having a detectable VL
significantly increased the odds of being a cigarette smoker. Many of the demographic and
clinical characteristics had significant associations with cigarette smoking (i.e., for every year
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older in age the log likelihood of the patient being a cigarette smoker increased; those who had a
diagnosis of substance abuse significantly increased the likelihood of being a cigarette smoker
whereas those on ART decreased the likelihood of being a cigarette smoker) in both bivariate
and multivariable analysis. These findings demonstrate the importance of utilizing home-based
VL monitoring device aimed at lowering the overall burden of CVD risk factors in YLH. By
identifying YLH at the highest risk could provide the necessary means of risk estimation and
communication in this population.
Chapter 4
In Chapter 4, we examined the association of detectable VL and single tablet regimen
and their contributions to lipid abnormalities in YLH. Our findings support the hypothesis that
VL non-suppression is associated with increased odds of lipid abnormalities and that STR is
found to be protective against lipid abnormalities. We found that having a detectable VL was
associated with significantly increased odds of the patient having low HDL but no significant
association was found with total cholesterol after adjusting for demographic and clinical
covariates and including STR in the model. On the other hand, treatment with STR was
associated with significantly decreased odds of the patient having low HDL cholesterol and high
total cholesterol. STRs provide many advantages for the management of HIV, including
improved adherence, lower health care costs, and greater patient satisfaction.14 However, these
regimens are relatively new on the drug market and each pill is a combination of multiple agents.
It is essential for a healthcare provider to describe each HIV regimen in more detail and discuss
possible side effects. Each regimen consists of two or more HIV drugs from the same or different
classes and these drugs may interact with other non-HIV medications. With youth increasingly
using technology, having an integrated patient portal linked with the EHR might be beneficial to
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improve health education relevant to their VL results, appointment reminders, prescription
refills, and drug interactions.
Although the use of STR was found to have favorable lipid profile, some ARTs such as
protease inhibitors may increase cholesterol, which could increase risk of CVD,12 and therefore,
the use of single tablet regimens and their impact on lipid profiles should be assessed over time.
However, the risks of not taking ARTs are much higher because having poorly controlled VL
leads to far worse health overall. Our finding suggests VL monitoring to ensure VL suppression
in YLH because suppression of HIV itself may be cardioprotective, possibly by reducing
proinflammatory cytokines (e.g., interleukin-6) that may play a role in arterial inflammation.15,16
Utilizing technology and promoting self-management (e.g., using home-based dried blood spot
as a VL monitoring device) may be beneficial to achieve VL suppression and eventually reduce
the prevalence of cardiometabolic risk factors in YLH.
In 2017, the U.S. was reported to be spending $324 billion, an astronomical amount in
comparison to other western and developed nations, on pharmaceutical drugs. As spending in
this sector continues to spiral out of control in the U.S., research in the foreseeable future needs
to address the impact this trend will have on the cost of healthcare and the implications from the
government on related policies; both consumers and politicians (Democratic candidates for the
Presidency) are already beginning to have serious concerns especially on the rising cost and
availability of these medications. One way to look at the issue is taking medication such as the
most commonly prescribed HIV medicines, single tablet regimens (e.g., Atripla and Complera)
which are found to have favorable lipid profile. In order to look at the causal effect of these
drugs, future research would include conducting randomized controlled trials. However, the
more important issues concern the availability of these medications, and whether they will be
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affordable or not to the consumers. It is imperative that future and additional research include
attempts to look closely at the rising trend in costs and availability with one eye on the policies
the government is expected to introduce in order to counter these issues.

Key Strengths
This dissertation has several key strengths. This is the first investigation to use
multivariable modeling to examine the independent contributions of biomarkers, behavioral
measures and ART medications on CVD risk in a U.S. population of adolescents and young
adults with HIV treated in routine practice. The use of multivariable models based on routinely
available EHR data integrated into a common data model is an innovative approach to improving
our understanding of important population health risk factors that may be modifiable in routine
practice. EMRs provided us with the opportunity to include three innovative design features in
this dissertation: (a) the inclusion of HIV outcomes data from clinic-based patients will lower
costs of testing for virologic and immunologic biomarkers; (b) the inclusion of ICD-10 codes to
identify diagnosis for cigarette smoking, diabetes, and substance abuse further identify
differences in the subgroups. The information gained may also provide valuable insight on how
to design future clinical trials. The results of this study will help tailor current practice guidelines
for CVD prevention in adolescents and young adults living with HIV.
The ATN clinics serve people from diverse ethnic and racial backgrounds. A strength of
this dissertation is that the National Heart, Lung, and Blood Institute (NHLBI) networks provide
a platform to study adequate numbers of patients with CVD risk factors, and serve as a vehicle
for translational research. This investigation takes advantage of a methodologically rigorous
design, including the use of a conceptual framework and routinely available EHR data integrated
into a common data model. This is a major advantage over other forms of epidemiological study
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as routinely collected data allow large cross-sectional studies to be made at little or no expense
but may give stronger evidence. This study will provide a platform to identify the landscape of
standards to improve our understanding of an underrepresented population health risk factors that
may be modifiable in routine practice. It will also provide a foundation to improve
cardiovascular health assessment practices in HIV prevention and treatment clinics nationwide.
Another advantage is that a cross-sectional study can be conducted as the first step either before
planning a cohort study or baselining in a cohort study.17,18 These study designs are the best way
to determine prevalence and are useful at identifying associations that can then be more
rigorously studied using a randomized controlled trial,19 or to design future clinical trials for
medical product development.
Another strength of this dissertation is its use of a sophisticated analytical model to
examine the relationships between the independent variables and outcomes and generate
regression models after adjustment for confounders. This investigation is innovative in that we
constructed a single multivariable risk function tailored to YLH by integrating into the existing
CVD prediction algorithm developed based on data obtained from the Framingham Heart Study.6
Given that the strongest predictor of cardiovascular risk in any risk equation is age and that
almost all multivariable risk algorithms are commonly used to assess risk of CVD events in older
adults and general population,6,20 this is the first study to develop cardiovascular risk profile with
age assumed to be 21 and construct Cardiac Risk Scores that estimate risk of developing CVD at
10 years for YLH without overt CVD events.

Limitations
Despite significant benefits, study limitations exist. Given that the 154 ATN Cascade
Monitoring is a nationwide study capturing data from 10 different clinics across the nation, the

110

findings of this dissertation are theoretically generalizable to YLH who reside in one of the 7
cities (Baltimore, Birmingham, Los Angeles, Memphis, Tampa, Washington, Miami).
Unfortunately, these are urban areas and the study cannot be generalized to YLH in rural areas of
the U.S. EHR is beneficial as it reduces secondary data entry error when creating data files
shared between sites and the data management team, and does not rely on youth self-report of
health. EHRs can also be leveraged to accomplish public health objectives in surveillance and
predictions. With the 154 ATN Cascade Monitoring being a cross-project initiative of the larger
network trial, we were able to obtain the EHR baseline data that is specific and verified, gathered
relatively quickly in large quantities, and hence a virtual cohort of YLH was created. Although
clinic-based studies have uncovered important biomedical associations between HIV and HIV
related care variables, they are limited in their ability to answer social and behavioral questions
and to generalize to larger populations.21 Since this investigation doesn’t have a comparison
group of HIV-negative youth, it might not be possible to draw conclusions and make broad
policy recommendations.
Although there are 7 ATN clinic sites participating in this dissertation, the majority of
them are located on the Eastern part of the U.S. As a result, YLH who live in other parts of the
U.S., mainly the Midwest, Southwest, and West, are not included in this study. As mentioned
above, all clinics are situated in major cities. YLH living in smaller cities or in rural areas are
also excluded. This potentially biases the sample, as YLH in non-urban areas experience
different barriers to accessing and staying in care. For instance, those in urban areas may have
greater access to public transportation and do not have to rely on cars or parking to visit a clinic.
In addition, those in non-urban areas may have fewer clinics nearby, experience greater stigma
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from their community, or receive less structural support (in the form of policy or provider
availability) for HIV-related care.
A possible threat to external validity of this study is the small sample sizes and missing
data for certain sites. We addressed this issue at the outset by merging data from all 10 sites to
increase the overall size of the dataset. Critics argue that it is difficult to derive causal
relationships from cross-sectional analysis since this is a one-time measurement of exposure and
outcome.17 A cross-sectional design can demonstrate associations but the study design makes it
difficult to determine the direction of causality.22,23 Because data on each patient are recorded
only once, it would be difficult to infer the temporal association between a risk factor and an
outcome.24,25 While we might be able to see associations between independent contributions of
biomarkers, behavioral measures, and ART medications on CVD risk among YLH in the U.S.,
observational studies are not intended to prove causation, and causal inferences should be
interpreted with caution.26 Misclassification, recall, selection, and interviewer bias lead to
systematic error in the causal inferences drawn from the analyses, which are threats to internal
validity that produce untrue associations between exposure and outcome.26 Although we adjusted
measure of effect using regression by adding confounders as independent variables in the model,
it is still possilbe to have residual confounding and it can bias the effect in any direction (towards
or away from the null).27

Overall Conclusion and Future Directions
As demonstrated in this dissertation, overall, the variety of biomedical and behavioral
factors that make HIV-positive individuals more susceptible to developing CVD is compelling
evidence to reconfigure how the two ailments are addressed. Because many of the risk factors for
CVD, including smoking and those analyzed in our three studies, can be managed by lifestyle
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intervention, it is important that these changes take place as early as possible, which makes youth
and young adults living with HIV an important target group. Their future risk of CVD with and
without intervention can be assessed with regression models to help come up with prevention
strategies. It is therefore important to focus specifically on this population because of the greater
opportunity to make changes to therapy and lifestyle that can lead to a better overall quality of
life and a decrease in the rate of morbidity and mortality. Future research must develop
prediction models for simultaneously assessing risk and providing treatment for HIV and CVD,
especially as ART both continues to improve the life expectancy for HIV-positive individuals
and pose a risk for developing CVD. The knowledge gained from this investigation can help
define guidelines and polices for care providers to assess and treat CVD risk factors in YLH as
well as potentially develop cutting edge tools for HIV-positive youth to assess cardiovascular
risk such as a cardiovascular risk assessment tailored to HIV-positive population. Some studies
suggest that with each year an individual on ART ages, their risk for CVD increases because of
ART’s effect on blood cholesterol and triglycerides,28,29 this would be a possible hypothesis for
future investigation.
The three studies included in this dissertation demonstrate that detectable VL per se may
lead to greater prevalence of cigarette smoking and lipid abnormalities with increased risk of
CVD. However, we used a cross-sectional study design and these studies did not have matched
controls. Until appropriately designed research studies examine absolute relative risk between
HIV-positive and HIV-negative individuals, ascertained risk is still not known. CVD risk does
not appear to rapidly increase in HIV-positive individuals with age. Earlier interventions for
reducing modifiable risk factors, such as smoking, obesity, blood pressure, cholesterol, and
diagnosing prediabetes, can significantly decrease the risk for CVD.30 Regular doctor visits for
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HIV care may provide additional opportunities for counseling, monitoring, and interventions for
modifiable CVD risk factors, more so than for general population.30 By knowing how many
modifiable CVD risk factors and what type patients have, patients and their health care providers
can make a customized plan of action to prevent, delay, or control these modifiable CVD risk
factors. Risk modification would include smoking cessation, cholesterol reduction, and blood
sugar and systolic blood pressure reduction.30
Historically, studies that have established associations between HIV, CVD risk factors,
and CVD, focused on older populations that have experienced cardiovascular events, and these
findings were then generalized back to the broader HIV-positive population. A more current
focus on reducing health disparities among sub-populations, however, highlights the need to
include younger age groups to whom study results will be applied31 to mitigate the chance of
premature cardiovascular events and CVDs. This type of study design is important for
descriptive analyses and for generating hypotheses using the cardiovascular framework to
understand the relationship between HIV-related factors and CVD among adolescents and young
adults with HIV or those at risk for HIV in the U.S. With the use of EHRs, we can use data from
a large number of subjects and, unlike observational studies, is not geographically bound.32
Future directions include creating a systematic centralized database and conducting longitudinal
data analyses to analyze trajectories of change in the cardiovascular health-related characteristics
over time . Using a network-based recruitment approach to identify HIV-positive and HIVnegative youth, researchers can develop prediction models and tailored treatment options for
YLH. The knowledge gained from these studies will facilitate dissemination and advocate for
creating and implementing policies and guidelines.
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Taken together, this dissertation demonstrates that a relationship exists between
detectable VL and increased risk of CVD; and cigarette smoking may lead to VL nonsuppression, which then lead to lipid abnormalities but the mechanics are poorly understood.
When studying the young population in any aspect, it tends to be challenging to eliminate many
factors that may be affecting treatment methods, from related diseases, and disorders to even
societal challenges. The targeted population YLH carries a lot of interconnected factors that act
as a tide in the ocean against seeking them, and it requires a multidisciplinary treatment method
to increase its effectiveness in biological, societal, and even psychological way. These factors
that tend to be overlooked as a whole may discourage a patient from a critical stage of treatment,
or even taking the step to begin with treatment and it may increase having secondary diseases,
such as CVD.

References
1.
2.

3.

4.

5.

6.
7.

8.

Naar S, Parsons JT, Stanton BF. Adolescent Trials Network for HIV-AIDS Scale It Up
Program: Protocol for a Rational and Overview. JMIR Res Protoc. 2019;8(2):e11204.
Pennar AL, Dark T, Simpson KN, et al. Cascade Monitoring in Multidisciplinary
Adolescent HIV Care Settings: Protocol for Utilizing Electronic Health Records. JMIR
Res Protoc. 2019;8(5):e11185.
Wong VJ, Murray KR, Phelps BR, Vermund SH, McCarraher DR. Adolescents, young
people, and the 90-90-90 goals: a call to improve HIV testing and linkage to treatment.
AIDS (London, England). 2017;31 Suppl 3:S191-s194.
Wilson PW. Overview of established risk factors for cardiovascular disease. 2018;
https://www.uptodate.com/contents/cardiovascular-disease-risk-assessment-for-primaryprevention-risk-calculators.
Berry JD, Lloyd-Jones DM, Garside DB, Greenland P. Framingham risk score and
prediction of coronary heart disease death in young men. American heart journal.
2007;154(1):80-86.
D’Agostino Ralph B, Vasan Ramachandran S, Pencina Michael J, et al. General
Cardiovascular Risk Profile for Use in Primary Care. Circulation. 2008;117(6):743-753.
Rubinstein ML, Harris DR, Rudy BJ, Kapogiannis BG, Aldrovandi GM, Mulligan K.
Exploration of the Effect of Tobacco Smoking on Metabolic Measures in Young People
Living with HIV. AIDS Research and Treatment. 2014;2014:8.
Santiprabhob J, Tanchaweng S, Maturapat S, et al. Metabolic Disorders in HIV-Infected
Adolescents Receiving Protease Inhibitors. BioMed research international.
2017;2017:7481597-7481597.
115

9.
10.
11.

12.

13.

14.
15.
16.
17.
18.
19.
20.

21.
22.

23.

24.
25.
26.
27.

El-Sadr W, Mullin C, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin
levels: results from a large antiretroviral-naïve cohort. HIV Medicine. 2005;6(2):114-121.
Jones CY. Metabolic Syndrome in HIV-Infected Patients: No Different than the General
Population? Clinical Infectious Diseases. 2007;44(5):735-738.
Worm SW, Sabin CA, Reiss P, et al. Presence of the Metabolic Syndrome Is Not a Better
Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected
Individuals. Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study.
2009;32(3):474-480.
Currier JS. Epidemiology of cardiovascular disease and risk factors in HIV-infected
patients. 2018; https://www.uptodate.com/contents/epidemiology-of-cardiovasculardisease-and-risk-factors-in-hiv-infected-patients.
Hadigan C, Meigs JB, Wilson PW, et al. Prediction of coronary heart disease risk in HIVinfected patients with fat redistribution. Clinical infectious diseases : an official
publication of the Infectious Diseases Society of America. 2003;36(7):909-916.
Truong WR, Schafer JJ, Short WR. Once-Daily, Single-Tablet Regimens For the
Treatment of HIV-1 Infection. P T. 2015;40(1):44-55.
Friis-Moller N, Reiss P, Sabin CA, et al. Class of Antiretroviral Drugs and the Risk of
Myocardial Infarction. New England Journal of Medicine. 2007;356(17):1723-1735.
Kuller LH, Tracy R, Belloso W, et al. Inflammatory and Coagulation Biomarkers and
Mortality in Patients with HIV Infection. PLOS Medicine. 2008;5(10):e203.
Setia MS. Methodology Series Module 3: Cross-sectional Studies. Indian Journal of
Dermatology. 2016;61(3):261-264.
Hulley SB, Cummings SR, Newman TB. Designing cross-sectional and cohort studies.
Section II Study Designs:84-96.
Mann CJ. Observational research methods. Research design II: cohort, cross sectional,
and case-control studies. Emergency Medicine Journal. 2003;20(1):54-60.
Wilson Peter WF, D’Agostino Ralph B, Levy D, Belanger Albert M, Silbershatz H,
Kannel William B. Prediction of Coronary Heart Disease Using Risk Factor Categories.
Circulation. 1998;97(18):1837-1847.
Yeatman S, Trinitapoli J, Hayford S. Limitations of clinic-based studies on HIV and
fertility preferences. American journal of public health. 2013;103(6):e5-e5.
Worke MD, Bezabih LM, Woldetasdik MA. Utilization of contraception among sexually
active HIV positive women attending art clinic in University of Gondar Hospital: a
hospital based cross-sectional study. BMC Women's Health. 2016;16:1-9.
Kiderlen TR, Conteh M, Roll S, Seeling S, Weinmann S. Cross-Sectional Study
Assessing HIV Related Knowledge, Attitudes and Behavior in Namibian Public Sector
Employees in Capital and Regional Settings. PLoS ONE. 2013;8(9):e75593.
ENDGAMES. BMJ: British Medical Journal. 2014;348(7951):38-37.
Song JW, Chung KC. Observational Studies: Cohort and Case-Control Studies. Plastic
and reconstructive surgery. 2010;126(6):2234-2242.
Aschengrau A, Seage GR. Essentials of Epidemiology in Public Health. 3rd ed. Sudbury,
MA: Jones and Bartlett 2014.
Kelvin E. Internal Validity: Bias & Confounding [PowerPoint]. New York, NY: CUNY
Doctor of Public Health Program;2015.

116

28.

29.

30.
31.

32.

Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease following
smoking cessation in patients with HIV infection: results from the D:A:D study. HIV
Medicine. 2011;12(7):412-421.
Currier JS, Lundgren JD, Carr A, et al. Epidemiological Evidence for Cardiovascular
Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral
Therapy. Circulation. 2008;118(2):e29-e35.
Triant VA. HIV infection and coronary heart disease: an intersection of epidemics. The
Journal of infectious diseases. 2012;205 Suppl 3:S355-361.
Al-Kindi SG, ElAmm C, Ginwalla M, et al. Heart failure in patients with human
immunodeficiency virus infection: Epidemiology and management disparities.
International Journal of Cardiology. 2016;218:43-46.
Labaree RV. Organizing Your Social Sciences Research Paper. Research Guides 2018;
http://libguides.usc.edu/writingguide.

Appendix 1. Description of Dissertation Variables
Dependent
Variables
Cardiac Risk
Score1

AI
M
1

Cardiac Risk
Score2

1

Tobacco_Use

2

High Total
Cholesterol

3

Definition and Metrics

Type

Item Source

Defined as the Cardiac
Risk Score for patients
with systolic blood
pressure, cigarette, and
diabetes, and blood
pressure medications.
Defined as the Cardiac
Risk Score2 for
participants with total
cholesterol, HDL
cholesterol, systolic blood
pressure, smoking, and
diabetes, and blood
pressure medications.
1=Patient is reported to
have used tobacco if
ICD10 diagnosis codes
report tobacco use OR
Site reported tobacco use
by patient response
0=patient is reported to not
have used tobacco if site
reported no tobacco use by
patient response OR value
is missing.
Age 19 or younger: greater
than or equal to 170 mg/dL
Men age 20 or older:
greater than 200 mg/dL

Numeric

Developed for study per
guidance from D’Agostino et
al. (2008) General
Cardiovascular Risk Profile for
Use in Primary Care The
Framingham Heart Study
Developed for study per
guidance from D’Agostino et
al. (2008) General
Cardiovascular Risk Profile for
Use in Primary Care The
Framingham Heart Study

Numeric

Binary

Extracted EHR data

Binary

NIH guidelines for children’s
cholesterol.
https://www.nhlbi.nih.gov/heal
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Women age 20 or older:
greater than 200 mg/dL
Low HDL

3

Independent
Variables
VL_Results

AI
M
1, 2,
3

VL_UND

1, 2,
3

CD4_Results

1

AIDS

1

Metabolic
syndrome
(MetSyn)

2

th-topics/high-bloodcholesterol

Age 19 or younger: less
than or equal to 45 mg/dL
Men age 20 or older: less
than 40 mg/dL
Women age 20 or older:
less than 50 mg/dL
Definition and Metrics

Binary

NIH guidelines for children’s
cholesterol.
https://www.nhlbi.nih.gov/heal
th-topics/high-bloodcholesterol

Type

Item Source

Viral Load values as
reported: “copies/mL”
• Earliest date
reported value
• Results that were
reported at or
below detection
level were
assumed 1 value
below detection
level
1=Patient’s viral load
result was below the
detectable threshold as
reported by site
0=Patient’s viral load was
above the detectable
threshold as reported by
site
Continuous variable:
baseline CD4 cell count
results with absolute count.
CD4 values as reported:
Specifically “cells/cumm”
for site WADC and “/uL”
for site TAFL
• Earliest date
reported value
1=CD4_results<=200
0=CD4_Results>200
3 or more of the following
criteria:
• Obesity
• Diabetes
• Hypertension
• Hypertriglyceride
mia
• Low HDL

Numeric

Extracted EHR data

Binary

Extracted EHR data (recoded
into a dichotomous variable)

Numeric

Extracted EHR data

Binary

Extracted EHR data (recoded
into a dichotomous variable)
3
NHLBI definition; Al-Hamad
categories: (2017) Metabolic syndrome in
0-1
children and adolescents;
component Jaggers et al. (2014); Magge et
s of
al. (2017)
MetSyn; 2
component
s of
MetSyn;
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DrugCode_4

3

Single tablet regimen

Demographic
and Other
Clinical
Variables
Age

AI
M

Definition and Metrics

1, 2,
3

Race/Ethnicity

1, 2,
3

Gender

1, 2,
3
1, 2,
3

Continuous variable in
year. Years as reported by
site.
Race as reported by site.
Categorical variable with
four options: Black,
Latino, White, and Other.
1=Sex of patient is male
0=Sex of patient is female
Tallest and earliest date
reported value for height
and highest and earliest
date reported value for
weight were used.
1=Patient is on HIV
medication
0=Patient was not
reportedly on HIV
Medication
BEMD= Baltimore
Maryland
BMAL= Birmingham
Alabama
BNNY=Brooklyn New
York
LACA= Los Angeles
California
MIFL= Miami Florida
MSTN= Memphis
Tennessee
PAPA= Philadelphia
Pennsylvania
SDCA= San Diego
California
TAFL= Tampa Florida
WADC= Washington DC
ICD 10 codes F1010,
F1210, F1220, F1290,

BMI

ART_Meds

1, 2,
3

Site

1

Substance_Abuse

1, 2,
3

and 3 or
more
component
s of
MetSyn
Binary
Extracted EHR data (HIV
medication data files classified
and coded)
Type
Item Source

Numeric

Extracted EHR data

Categorica
l

Extracted EHR data (recoded
into 4 categories)

Binary

Extracted EHR data

Numeric

Extracted EHR data

Binary

Extracted and coded EHR data
files

Character

Extracted EHR data

Numeric

Extracted EHR data (recoded
into dichotomous variable)
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F1510, F1511, F1520,
F1590, F17200, F17210,
F1910, and F1920 to
identify alcohol and drug
problems that are recorded
in the EHR systems.
1 = Patient is diagnosed
with substance abuse
0 = Patient was not
diagnosed with substance
abuse
BP_Systolic

1, 2,
3
1, 2,
3

Systolic Blood pressure
value as reported by site
1= patient was reported by
site to be prescribed
hypertension medication
0=patient was not reported
by site to be prescribed
hypertension medication

Diabetes

2

1=Patient is reported to
have diabetes if ICD10
diagnosis codes report
diabetes OR blood test
results exceed
predetermined criteria
0=patient is reported to not
have diabetes if patient
does not meet
predetermined criteria OR
value is missing.

Binary

Obesity

2

Patients who were between
20 and 24 with a BMI over
30 would be classified as
obese; patients who were
between 14 and 19 with a
BMI at or above the 95th
percentile of children of
the same age and sex
would be considered to
have obesity.

Binary

HTN_DRUG

Numeric
Binary

Extracted EHR data
Extracted EHR data (HTN
drugs coded)
HTN_DRUG=1 if patient drug
prescriptions contained any of
the following:
Amlodipine Desylate
Enalapril
Lisinopril
Spironolactone
Else HTN_DRUG=0
Extracted EHR data
ICD10 Diagnosis Codes:
E10XX, E11XX or E13XX
Patients without these ICD10
diagnosis codes were given a
missing value for diabetes and
evaluated for Predetermined
Criteria:
Diabetes=1
BG_HbA1c results>6.0
OR
BG_fasting>110
OR
Blood_Glucose>180
Else, Diabetes=0
Developed for study per
guidance from the CDC
downloaded percentile data
files on growth charts to
calculate the 95th percentile
values by sex and age.
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Hypertension

2

Systolic blood pressure ≥
130 mmHg or treatment
with anti-hypertensive
medication

Numeric

High triglycerides

2

Triglyceride ≥ 150 mg/dl

Binary

DrugCode_COU
NT

3

1 means patients were only
on one type of ART. 2
means patients were on
two types of ART. 3
means patients were on 3
types of ART. 4 means
patients were prescribed
on 4 types of ART. 5
means patients were
prescribed on 5 types of
ART. If data are missing
for this variable it means
that no drug is coded for
the patient.

Categorica
l

DrugCode_1

3

Binary

DrugCode_2

3

DrugCode_3

3

Nucleoside reverse
transcriptase inhibitor
(NRTI)
Non-nucleoside reverse
transcriptase inhibitor
(NNRTI)
Protease inhibitor (PI)

DrugCode_5

3

Integrase inhibitor (II)

Binary

High LDL
Cholesterol

3

Age 19 or younger: greater
than or equal to 100 mg/dL
Men age 20 or older:
greater than or equal to
100 mg/dL
Women age 20 or older:
greater than or equal to
100 mg/dL

Binary

Binary

Binary

NHLBI/NCEP III (Hamad and
Raman 2017); IDF definition
ages 16+ adult and pediatric
(Hamad and Raman 2017 and
Magge et al 2017); Jaggers et
al 2014
Hamad and Raman 2017;
Magge et al 2017
Extracted EHR data
(recoded into a categorical
variable)

Extracted EHR data (HIV
medication data files classified
and coded)
Extracted EHR data (HIV
medication data files classified
and coded)
Extracted EHR data (HIV
medication data files classified
and coded)
Extracted EHR data (HIV
medication data files classified
and coded)
NIH guidelines for children’s
cholesterol.
https://www.nhlbi.nih.gov/heal
th-topics/high-bloodcholesterol
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